UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 13, 1998
-------------------
fonix corporation
- ---------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware
- ---------------------------------------------------------------------------
(State or other jurisdiction of incorporation or organization)
0-23862 22-2994719
- --------------------------- ------------------------------------
(Commission file number) (I.R.S. Employer Identification No.)
1225 Eagle Gate Tower, 60 East South Temple Street
Salt Lake City, Utah 84111
--------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (801) 328-0161
Not Applicable
- ---------------------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE>
ITEM 2. ACQUISITION OR DISPOSITION OF ASSETS
On January 13, 1998, fonix corporation, a Delaware corporation, (the
"Company" or "fonix") entered into an Agreement and Plan of Reorganization
(the "Merger Agreement") by and among fonix, fonix Acquisition Corporation, a
Utah corporation and wholly-owned subsidiary of fonix ("FAC"), and AcuVoice,
Inc., a California corporation ("AcuVoice"). Pursuant to the Merger
Agreement, AcuVoice would be merged (the "Merger") with and into FAC, with FAC
being the surviving entity. Prior to the merger, there was no material
relationship between fonix and any of its affiliates, directors or executive
officers, on the one hand, and AcuVoice or any of its affiliates, directors or
executive officers, on the other hand. The Merger was unanimously approved
and recommended to their respective shareholders by the boards of directors of
FAC and AcuVoice, and was approved by the affirmative vote of a majority of
the shareholders of both AcuVoice and FAC, as required by the law of the
states of California and Utah, respectively. The Merger was also approved by
the board of directors of fonix. The transactions contemplated by the Merger
Agreement were consummated, in part, on March 13, 1998 (the "Closing"), as is
described below.
Background of the Merger
AcuVoice was incorporated in 1984, and since that time has been engaged
in the development of a text-to-human-speech synthesis technology called
"concatenative speech synthesis," a software-only approach now recognized in
the speech technology industry as a leading method of achieving natural
sounding speech from a computer. AcuVoice's primary assets consist of
technology and know-how with respect to its voice synthesis technologies.
Such assets are not represented by patents, but are trade secrets and other
forms of intellectual property that are closely protected by AcuVoice and will
be made available to fonix after the Merger.
fonix, since 1994, has been engaged in research and development of
certain proprietary automatic computer voice recognition and related
technologies (collectively the "Core Technologies"). fonix believes that
voice synthesis technology is an important complementary technology to fonix's
proprietary Core Technologies, and prior to the Merger, fonix had already
commenced developing certain voice synthesis technologies.
fonix was introduced to AcuVoice by John A. Oberteuffer, Ph.D., a leading
expert in the field of speech recognition and speech synthesis technologies,
who since March 1997 has served on the fonix Board, and who presently is
employed as fonix's Vice President--Technology. As of that time, and
continuing to the present, Dr. Oberteuffer had no affiliation with or interest
in AcuVoice of any type.
fonix management believes that the AcuVoice technologies will be an
important and complementary addition to the suite of Core Technologies fonix
has developed to date and is in the process of developing. fonix management
also believes that a state-of-the-art voice synthesis technology, coupled with
fonix's Core Technologies, will substantially increase the marketability of
both technologies by broadening the potential product applications, thereby
increasing the pool of potential licensees of
2
<PAGE>
the technologies. There can be no assurance, however, that AcuVoice's
technologies will be successfully integrated with the fonix Core Technologies
or that significant marketing opportunities will accrue to fonix as a result
of the Merger.
Terms of the Merger
The Merger Agreement provided for the incorporation of FAC which, after
the consummation of the Merger, would continue the business of AcuVoice as a
wholly-owned subsidiary of fonix. Pursuant to the Merger, FAC is to acquire
all of the assets and assume all of the liabilities of AcuVoice. Upon the
filing of a certificate of merger with the Secretary of State of California
and the Utah Department of Commerce (the "Effective Date"), the separate
corporate existence of AcuVoice will cease. FAC will continue the operations
of AcuVoice after the consummation of the Merger under FAC's Articles of
Incorporation and Bylaws. Although the Closing has occurred, and the
consideration for the Merger has been exchanged, as is described below, the
Effective Date has not yet occurred pending the issuance by the California
Secretary of State of a tax clearance certificate. Immediately after the
issuance of such clearance certificate, fonix and AcuVoice will each file the
certificate of merger with the Secretary of State of California and the Utah
Department of Commerce. The Merger Agreement provides that the directors and
officers of AcuVoice each resign their positions immediately before the
Effective Date in favor of the directors and officers of FAC. The principal
executive offices of FAC upon the Effective Date will be 84 West Santa Clara
Street, San Jose, California 95113.
Consideration
As consideration for fonix's acquisition by merger of AcuVoice, fonix
tendered to the shareholders of AcuVoice, in the aggregate, (i) 2,692,218
shares of the restricted common stock of fonix, and (ii) $8,000,232. The
method of calculating the amount of such consideration was as follows:
At Closing, each share of common stock of AcuVoice (the Merger Agreement
required conversion of all AcuVoice preferred stock into AcuVoice common stock
as a condition of closing) outstanding immediately prior to Closing was
exchanged for (i) that number of validly issued, fully paid and nonassessable
shares of fonix restricted common stock which equals the amount obtained by
dividing (A) the quotient of (1) $12,000,000 divided by (2) the Closing Price,
as that term is defined below by (B) the number of shares of AcuVoice common
stock outstanding immediately prior to the Closing, and (ii) cash in the
amount of $8,000,000 divided by the number of outstanding shares of AcuVoice
Common Stock. "Closing Price" is a sum equal to the average of the closing
bid price of a share of fonix common stock during the 10 trading day period
immediately preceding each of the following dates: (x) November 12, 1997, (y)
January 13, 1998; and (z) March 2, 1998.
The total purchase price was determined pursuant to arms-length negotiation
s between fonix and AcuVoice. As indicated in the Merger Agreement, the
parties to the Merger Agreement valued the 2,692,218 shares of the Company's
common stock which were exchanged for the outstanding
3
<PAGE>
shares of AcuVoice common stock at $12,000,000 or approximately $4.45 per
share, in addition to the aggregate cash payment of approximately $8,000,000.
Notwithstanding this valuation by the parties to the Merger Agreement,
the fair market value of the fonix common stock issued to the shareholders of
AcuVoice is $6 5/16 per share, or $16,994,626 in the aggregate, based on the
closing bid price of the Company's common stock as quoted by the Nasdaq
SmallCap market on March 13, 1998. After the merger, the former shareholders
of AcuVoice, constituting 52 persons, beneficially own 5.25% of the total
51,303,521 shares of fonix common stock issued and outstanding as of the date
hereof.
Prior to the Effective Date, the Merged Corporation's principal place of
business was San Jose, California, and its principal executive offices were
located at 84 West Santa Clara Street, San Jose, California 95113. At that
address, AcuVoice occupied approximately 1,620 square feet of office space,
which is leased on a month-to-month basis. Pursuant to the Merger, fonix,
through FAC, has agreed to assume that lease and will continue the business
operations of AcuVoice at that location, although the principal executive
offices of the Company and FAC will be located in Salt Lake City Utah, at
fonix's corporate headquarters.
Prior to the Merger, AcuVoice owned or leased the equipment used in its
business. After the Merger, FAC intends to continue to use the same equipment
(whether owned or leased by AcuVoice) for the same business as was conducted
by AcuVoice prior to the Merger.
The cash component of the Merger consideration was obtained by fonix
pursuant to a private placement of its restricted common stock that was
consummated on March 12, 1998.
Additional Terms
Pursuant to an Escrow Agreement executed on March 13, 1998, fonix and
AcuVoice agreed to place 80,000 shares of the fonix common stock issued as
consideration for the Merger in escrow as the sole recourse of fonix in the
event of any breach by AcuVoice of the representations and warranties included
in the Merger Agreement. The term of the escrow arrangement is one year,
after the expiration of which, the shares deposited into escrow, less any
amount deemed to be payment to fonix for damages suffered as a result of any
breach by AcuVoice, is to be remitted, pro-rata, to the AcuVoice shareholders
in proportion to the percentage of AcuVoice common stock owned by them prior
to the consummation of the Merger.
Additionally, the Company and E. David Barton, an executive officer and
the majority shareholder of AcuVoice, executed a Technology Purchase Option on
March 13, 1998, pursuant to which E. David Barton will have the right to
purchase a nonexclusive, perpetual, transferable, royalty-free license to the
AcuVoice technology in the event of any voluntary or involuntary appointment
of a trustee, receiver or custodian for FAC who is not discharged within 120
days, or in the event of any bankruptcy or insolvency proceeding, voluntary or
involuntary insolvency proceeding, in either case, which is not resolved
within 120 days.
4
<PAGE>
Item 7. Financial Statements and Exhibits.
(a) Financial Statements of Business Acquired.
It is impracticable for the Company to provide the required financial
statements of AcuVoice as required by Item 7(a) of Form 8-K on the date
hereof. The Company undertakes that it will file by amendment the required
audited financial statements for AcuVoice within the time period allowed by
Form 8-K.
(b) Pro Forma Financial Information.
It is impracticable for the Company to provide the required pro forma
financial information as required by Item 7(b)of Form 8-K. The Company
undertakes that it will file the required pro forma financial information or
AcuVoice within the time period allowed by Form 8-K.
(c) Exhibits. The following are filed as exhibits to this Current
Report:
Exhibit
No. Description
------- -------------------------------------------------
(2) Agreement and Plan of Reorganization among fonix, FAC and
AcuVoice, dated as of January 13, 1998.
Pursuant to Item 601(b)(2) of Regulation S-K, the exhibits
and schedules to the Agreement and Plan of Reorganization are
not filed herewith. The exhibits and schedules identified in
the Agreement and Plan of Reorganization, but that are not filed
herewith will be provided to the Commission upon request
therefor.
5
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
fonix corporation
By: /s/ Stephen M. Studdert
------------------------------------
Stephen M. Studdert,
Chairman and Chief Executive Officer
Date: March 30, 1998
<PAGE>
EXHIBIT INDEX
Exhibit
No. Description
------- -------------------------------------------------
(2) Agreement and Plan of Reorganization among fonix, FAC and
AcuVoice, dated as of January 13, 1998.
Pursuant to Item 601(b)(2) of Regulation S-K, the exhibits
and schedules to the Agreement and Plan of Reorganization are
not filed herewith. The exhibits and schedules identified in
the Agreement and Plan of Reorganization, but that are not filed
herewith will be provided to the Commission upon request
therefor.
AGREEMENT AND PLAN OF REORGANIZATION
BY AND AMONG
fonix corporation,
fonix ACQUISITION CORPORATION,
AND
ACUVOICE, INC.
January 13, 1998
<PAGE>
TABLE OF CONTENTS
1. The Merger...................................................1
1.1 The Merger.............................................1
1.2 Closing; Effective Time................................1
1.3 Effect of the Merger...................................2
1.4 Articles of Incorporation; Bylaws......................2
1.5 Directors and Officers.................................2
1.6 Effect on Capital Stock................................2
1.7 Surrender of Certificates..............................4
1.8 No Further Ownership Rights in AcuVoice Common
Stock..................................................6
1.9 Lost, Stolen or Destroyed Certificates.................7
1.10 Tax Consequences......................................7
1.11 Taking of Necessary Action; Further Action............7
2. Conditions to the Merger.....................................7
2.1 Conditions to Obligations of Each Party to Effect
the Merger.............................................7
2.2 Additional Conditions to Obligations of AcuVoice.......8
2.3 Additional Conditions to Obligations of fonix and
Merger Sub.............................................9
3. Representations and Warranties of AcuVoice..................11
3.1 Organization, Standing and Power......................11
3.2 Authority.............................................12
3.3 Governmental Authority................................12
3.4 Capital Structure.....................................13
3.5 Financial Statements..................................13
3.6 Absence of Certain Changes............................14
3.7 Absence of Undisclosed Liabilities....................16
3.8 Litigation............................................16
3.9 Restrictions on Business Activities...................16
3.10 Intellectual Property................................16
3.11 Interested Party Transactions........................19
3.12 Minute Books.........................................19
3.13 Complete Copies of Materials.........................19
3.14 Material Contracts...................................19
3.15 Accounts Receivable..................................19
3.16 Customers and Suppliers..............................20
3.17 Employees and Consultants............................20
3.18 Title to Property....................................20
3.19 Environmental Matters................................21
3.20 Taxes................................................21
3.21 Employee Benefit Plans...............................23
3.22 Employee Matters.....................................25
3.23 Insurance............................................25
3.24 Compliance with Laws.................................26
3.25 Brokers' and Finders' Fees...........................26
3.26 Questionable Payments................................26
3.27 Disclosure...........................................26
4. Representations and Warranties of fonix and Merger Sub......26
4.1 Organization, Standing and Power......................27
4.2 Capital Structure.....................................27
4.3 Authority.............................................27
4.4 SEC Documents; Financial Statements...................28
4.5 Absence of Certain Changes............................29
4.6 Absence of Undisclosed Liabilities....................29
4.7 Litigation............................................29
4.8 Governmental Authorization............................30
4.9 Broker's and Finders' Fees............................30
4.10 Interim Operations of Merger Sub.....................30
4.11 Post-Merger Operations of Merger Sub.................30
4.12 Representations Complete.............................30
5. Conduct Prior to the Effective Time.........................31
5.1 Conduct of Business of AcuVoice and fonix.............31
5.2 Conduct of Business of AcuVoice.......................32
5.3 No Solicitation.......................................34
6. Additional Agreements.......................................34
6.1 Preparation of Solicitation Statement.................34
6.2 Approval of Shareholders..............................35
6.3 Sale of Shares Pursuant to Section 4(2) of the
Securities Act........................................36
6.4 Access to Information.................................36
6.5 Confidentiality.......................................37
6.6 Public Disclosure.....................................37
6.7 Affiliate Agreement...................................37
6.8 Legal Requirements....................................37
6.9 Blue Sky Laws.........................................38
6.10 Escrow Agreement......................................38
6.11 Listing of Additional Shares..........................38
6.12 Employees.............................................38
6.13 Reorganization........................................38
6.14 Expenses..............................................38
6.15 Registration of Shares Issued in the Merger...........38
6.16 Reasonable Commercial Efforts and Further Assurances..42
7. Termination; Amendment and Waiver...........................43
7.1 Termination...........................................43
7.2 Effect of Termination.................................43
7.3 Amendment.............................................44
7.4 Extension; Waiver.....................................44
8. Escrow and Indemnification..................................44
8.1 Escrow Fund...........................................44
8.2 Indemnification.......................................45
8.3 Escrow Period; Release from Escrow....................45
8.4 Claims upon Escrow Fund...............................46
8.5 Objections to Claims..................................47
8.6 Resolution of Conflicts and Arbitration...............47
8.7 Shareholders' Agent...................................48
8.8 Actions of the Shareholders' Agent....................49
8.9 Third-Party Claims....................................49
9. General Provisions..........................................49
9.1 Notices...............................................49
9.2 Definitions...........................................51
9.3 Counterparts..........................................51
9.4 Entire Agreement; Nonassignability; Parties in
Interest..............................................51
9.5 Severability..........................................51
9.6 Remedies Cumulative...................................51
9.7 Governing Law.........................................51
9.8 Rules of Construction.................................52
9.9 Amendment.............................................52
9.10 Expenses..............................................52
9.11 Extension; Waiver.....................................52
9.12 No Transfer...........................................52
9.13 Further Assurances....................................52
9.14 Absence of Third Party Beneficiary Rights.............53
<PAGE>List of Exhibits
Exhibit A Certificate of Merger
Exhibit B-1 Legal Opinion of Durham, Evans, Jones & Pinegar
Exhibit B-2 Legal Opinion of Wilson Sonsini Goodrich & Rosati
Exhibit C Escrow Agreement
Exhibit D Form of Affiliate Agreement
Exhibit E Offer Letter
Exhibit F Technology Purchase Option Agreement
Exhibit G -Tax Matters Agreement
<PAGE>
AGREEMENT AND PLAN OF REORGANIZATION
This AGREEMENT AND PLAN OF REORGANIZATION (the "Agreement") is made and
entered into as of January 13, 1998 by and among fonix corporation, a Delaware
corporation ("fonix"), fonix Acquisition Corporation, a Utah corporation and
wholly owned subsidiary of fonix ("Merger Sub"), and AcuVoice, Inc., a
California corporation ("AcuVoice").
RECITALS
A. The Boards of Directors of AcuVoice, fonix and Merger Sub believe
it is in the best interests of their respective companies that AcuVoice and
Merger Sub combine into a single company through the statutory merger of
AcuVoice with and into Merger Sub (the "Merger") and, in furtherance thereof,
have approved the Merger.
B. Pursuant to the Merger, among other things, the outstanding shares
of AcuVoice common stock (the "AcuVoice Common Stock") shall be converted into
shares of the right to receive the Merger Consideration (as defined in Section
1.6(a)) (assuming the conversion of all outstanding shares of AcuVoice
preferred stock ("AcuVoice Preferred Stock")) upon the terms and subject to
the conditions set forth herein.
C. AcuVoice, fonix and Merger Sub desire to make certain
representations and warranties and other agreements among one another in
connection with the Merger.
D. The parties intend, by executing this Agreement, to adopt a plan
of reorganization within the meaning of Section 368 of the Internal Revenue
Code of 1986, as amended (the "Code"), and to cause the Merger to qualify as a
reorganization under the provisions of Section 368(a) of the Code.
NOW, THEREFORE, in consideration of the covenants and representations set
forth herein, and for other good and valuable consideration, the parties agree
as follows:
1. The Merger.
1.1 The Merger. At the Effective Time (as defined in Section
1.2) and subject to and upon the terms and conditions of this Agreement, the
Certificate of Merger attached hereto as Exhibit A (the "Certificate of
Merger") and the applicable provisions of the Utah Revised Business
Corporations Act ("Utah Law") and the California Corporations Code
("California Law"), AcuVoice shall be merged with and into Merger Sub, the
separate corporate existence of AcuVoice shall cease and Merger Sub shall
continue as the surviving corporation. Merger Sub as the surviving
corporation after the Merger is hereinafter sometimes referred to as the
"Surviving Corporation."
1.2 Closing; Effective Time. The closing of the transactions
contemplated hereby (the "Closing") shall take place as soon as practicable
after the satisfaction or waiver or each of the conditions set forth in
Section 2 hereof, but not later than five (5) business days thereafter, or at
such other time as the parties hereto agree (the "Closing Date"). The Closing
shall take place at the offices of Durham, Evans, Jones & Pinegar, 50 South
Main Street, Suite 850, Salt Lake City, Utah 84144, or at such other location
as the parties hereto agree. In connection with the Closing, the parties
hereto shall cause the Merger to be consummated by filing the Certificate of
Merger, together with the required officers' certificates, with the
Secretaries of State of the State of Utah and California, in accordance with
the relevant provisions of Utah Law and California Law (the time of such
filing being the "Effective Time").
1.3 Effect of the Merger. At the Effective Time, the effect of
the Merger shall be as provided in this Agreement, the Certificate of Merger
and the applicable provisions of California Law and Utah Law. Without
limiting the generality of the foregoing, and subject thereto, at the
Effective Time, all the property, rights, privileges, powers and franchises of
AcuVoice and Merger Sub shall vest in the Surviving Corporation, and all
debts, liabilities and duties of AcuVoice and Merger Sub shall become the
debts, liabilities and duties of the Surviving Corporation.
1.4 Articles of Incorporation; Bylaws.
(a) At the Effective Time, the Articles of Incorporation of
Merger Sub, as in effect immediately prior to the Effective Time, shall be the
Articles of Incorporation of the Surviving Corporation until thereafter
amended as provided by Utah Law and such Articles of Incorporation; provided,
however, that Section 1 of the Articles of Incorporation of the Surviving
Corporation shall be amended to read as follows: "The name of the corporation
is AcuVoice, Inc."
(b) The Bylaws of Merger Sub, as in effect immediately
prior to the Effective Time, shall be the Bylaws of the Surviving Corporation
until thereafter amended.
1.5 Directors and Officers. At the Effective Time, the
directors and officers of Merger Sub immediately prior to the Effective Time
shall be the directors and officers of the Surviving Corporation, until their
respective successors are duly elected or appointed and qualified.
1.6 Effect on Capital Stock. At the Effective Time, by virtue
of the Merger and without any action on the part of Merger Sub, AcuVoice or
the holders of any of the following securities:
(a) Conversion of AcuVoice Capital Stock. Each share of
AcuVoice Common Stock issued and outstanding immediately prior to the
Effective Time (assuming the conversion of all AcuVoice Preferred Stock into
AcuVoice Common Stock prior to the Effective Time) (the "Outstanding AcuVoice
Shares") shall be converted and exchanged, without any action on the part of
the holders thereof, into the right to receive the following (the "Merger
Consideration"): (i) that number of validly issued, fully paid and
nonassessable restricted shares of the Common Stock, $.0001 par value, of
fonix (the "fonix Common Stock"), which equals the amount obtained by dividing
(A) the quotient of (a) $12,000,000 divided by (b) the Closing Price (as
defined in Section 1.6(e) below) by (B) the number of Outstanding AcuVoice
Shares (the "Exchange Ratio"), subject to Section 1.6(f); and (ii) cash in the
amount of $8,000,000 divided by the number of Outstanding AcuVoice Shares (the
"Cash Payment").
(b) Cancellation of AcuVoice Capital Stock Owned by fonix.
At the Effective Time, each share of AcuVoice Common Stock and AcuVoice
Preferred Stock (collectively, "AcuVoice Capital Stock") owned by fonix or any
direct or indirect wholly owned subsidiary of fonix immediately prior to the
Effective Time shall be canceled and extinguished without any conversion
thereof.
(c) Capital Stock of Merger Sub. At the Effective Time,
each share of Common Stock of Merger Sub ("Merger Sub Common Stock") issued
and outstanding immediately prior to the Effective Time shall be converted
into and exchanged for one validly issued, fully paid and nonassessable share
of Common Stock of the Surviving Corporation. Each stock certificate of
Merger Sub evidencing ownership of any such shares shall continue to evidence
ownership of such shares of capital stock of the Surviving Corporation.
(d) Adjustments to Exchange Ratio. The Exchange Ratio
shall be adjusted to reflect fully the effect of any stock split, reverse
split, stock dividend (including any dividend or distribution of securities
convertible into fonix Common Stock or AcuVoice Common Stock), reorganization,
recapitalization or other like change with respect to fonix Common Stock or
AcuVoice Common Stock occurring after the date hereof and prior to the
Effective Time.
(e) Fractional Shares. No fraction of a share of fonix
Common Stock will be issued, but in lieu thereof, and to the extent not waived
in writing, each holder of shares of AcuVoice Common Stock who would otherwise
be entitled to a fraction of a share of fonix Common Stock (after aggregating
all fractional shares of fonix Common Stock to be received by such holder)
shall receive from fonix an amount of cash (rounded to the nearest whole cent)
equal to the product of (i) such fraction, multiplied by (ii) a sum equal to
the average of (1) the average closing "bid" price of a share of fonix Common
Stock for the ten (10) trading days immediately prior to November 12, 1997 as
reported on the Nasdaq SmallCap Market; (2) the average closing "bid" price of
a share of fonix Common Stock for the ten (10) trading days immediately prior
to January 13, 1998 as reported on the Nasdaq SmallCap Market; and (3) the
average closing "bid" price of a share of fonix Common Stock for the ten (10)
trading days immediately prior to the date on which fonix makes the first
public announcement pursuant to Section 6.6 hereof of the execution of this
Agreement, as reported on the Nasdaq SmallCap Market (the "Closing Price").
The fractional share interests of each AcuVoice shareholder shall be
aggregated, so that no AcuVoice shareholder shall receive cash in respect of
fractional share interests in an amount greater than the value of one full
share of fonix Common Stock.
(f) Dissenters' Rights. Dissenting AcuVoice Capital Stock
("Dissenting Shares"), if any, shall not be converted into the Merger
Consideration but shall instead be converted into the right to receive such
consideration as may be determined to be due with respect to such Dissenting
Shares pursuant to California Law. AcuVoice shall give fonix prompt notice of
any demand received by AcuVoice to require AcuVoice to purchase shares of
Outstanding AcuVoice Shares, and fonix shall have the right to direct and
participate in all negotiations and proceedings with respect to such demand.
AcuVoice agrees that, except with the prior written consent of fonix, or as
required under the California Law, it will not voluntarily make any payment
with respect to, or settle or offer to settle, any such purchase demand. Each
holder of Dissenting Shares ("Dissenting Shareholder") who, pursuant to the
provisions of California Law, becomes entitled to payment of the fair value
for shares of AcuVoice Capital Stock shall receive payment therefor (but only
after the value therefor shall have been agreed upon or finally determined
pursuant to such provisions). If, after the Effective Time, any Dissenting
Shares shall lose their status as Dissenting Shares, fonix shall issue and
deliver, upon surrender by such Dissenting Shareholder of a certificate or
certificates representing shares of AcuVoice Capital Stock, the Merger
Consideration to which such shareholder would otherwise be entitled under this
Section 1.6 and the Certificate of Merger less the Merger Consideration
allocable to such shareholder that has been deposited in the Escrow Fund (as
defined below) in respect of such shares of AcuVoice Common Stock pursuant to
Section 1.7(i) and Section 8 hereof.
(g) Certificate Legends. The shares of fonix Common Stock
to be issued pursuant to this Section 1 shall not have been registered and
shall be characterized as "restricted securities" under the federal securities
laws, and under such laws such shares may be resold without registration under
the Securities Act of 1933, as amended (the "Securities Act"), only in certain
limited circumstances. Each certificate evidencing shares of fonix Common
Stock to be issued pursuant to this Section 1 shall bear the following legend:
"THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT
AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
"ACT"). SUCH SHARES MAY NOT BE SOLD OR OTHERWISE TRANSFERRED IN THE ABSENCE
OF SUCH REGISTRATION WITHOUT AN EXEMPTION UNDER THE ACT OR AN OPINION OF LEGAL
COUNSEL REASONABLY ACCEPTABLE TO fonix THAT SUCH REGISTRATION IS NOT
REQUIRED."
and any legends required by state securities laws.
1.7 Surrender of Certificates.
(a) Exchange Agent. Continental Stock Transfer Co. shall
act as exchange agent (the "Exchange Agent") in the Merger.
(b) fonix to Provide Common Stock and Cash. At the
Closing, fonix shall supply or cause to be supplied to the Exchange Agent for
exchange in accordance with this Section 1 through such reasonable procedures
as fonix may adopt (i) certificates evidencing the shares of fonix Common
Stock issuable pursuant to Section 1.6(a) in exchange for the Outstanding
AcuVoice Shares, less the number of shares of fonix Common Stock to be
deposited into an escrow fund (the "Escrow Fund") pursuant to the requirements
of Section 1.7(i) and Section 8, (ii) the Cash Payment, and (iii) cash in an
amount sufficient to permit payment of cash in lieu of fractional shares
pursuant to Section 1.6(f) (collectively, the "Exchange Fund").
(c) Exchange Procedures. At the Effective Time, the
Surviving Corporation shall cause to be mailed or hand deliver to each holder
of record of a certificate or certificates (the "AcuVoice Certificates") which
immediately prior to the Effective Time represented outstanding shares of
AcuVoice Common Stock, whose shares were converted into the right to receive
shares of fonix Common Stock (and cash in lieu of fractional shares) pursuant
to Section 1.6, (i) a letter of transmittal (which shall specify that delivery
shall be effective, and risk of loss and title to the AcuVoice Certificates
shall pass, only upon receipt of the AcuVoice Certificates by the Exchange
Agent, and shall be in such form and have such other provisions as fonix may
reasonably specify), (ii) such other customary documents as may be required
pursuant to such instructions, including without limitation, a Form W-9, and
(iii) instructions for use in effecting the surrender of the AcuVoice
Certificates in exchange for certificates representing shares of fonix Common
Stock and the Cash Payment (and cash in lieu of fractional shares). Upon
surrender of an AcuVoice Certificate for cancellation to the Exchange Agent or
to such other agent or agents as may be appointed by fonix, together with such
letter of transmittal and other documents, duly completed and validly executed
in accordance with the instructions thereto, the holder of such AcuVoice
Certificate shall be entitled to receive in exchange therefor (A) a
certificate representing the number of whole shares of fonix Common Stock less
the number of shares of fonix Common Stock to be deposited in the Escrow Fund
on such holder's behalf pursuant to Sections 1.7(i) and 8 hereof, (B) any
dividends or other distributions to which such holder is entitled pursuant to
Section 1.7(d), (C) cash (without interest) in respect of fractional shares as
provided in Section 1.6(f) and (D) cash (without interest) in the amount of
the Cash Payment which such holder has the right to receive in accordance with
section 1.6 in respect of the shares of AcuVoice Common Stock formerly
evidenced by such AcuVoice Certificate, and the AcuVoice Certificate so
surrendered shall forthwith be canceled. Until so surrendered, each
outstanding AcuVoice Certificate that, prior to the Effective Time,
represented shares of AcuVoice Common Stock will be deemed from and after the
Effective Time, for all corporate purposes, other than the payment of
dividends, to evidence the ownership of the number of full shares of fonix
Common Stock into which such shares of AcuVoice Common Stock shall have been
so converted, cash in the amount of the Cash Payment to which the holder is
entitled pursuant to Section 1.6, and the right to receive an amount in cash
in lieu of the issuance of any fractional shares in accordance with Section
1.6.
(d) Distributions with Respect to Unexchanged Shares. No
dividends or other distributions with respect to fonix Common Stock with a
record date after the Effective Time will be paid to the holder of any
unsurrendered AcuVoice Certificate with respect to the shares of fonix Common
Stock represented thereby until the holder of record of such AcuVoice
Certificate shall surrender such AcuVoice Certificate. Subject to applicable
law, following surrender of any such AcuVoice Certificate, there shall be paid
to the record holder of the certificates representing whole shares of fonix
Common Stock issued in exchange therefor, without interest at the time of such
surrender, the amount of any such dividends or other distributions with a
record date after the Effective Time theretofore payable (but for the
provisions of this Section 1.7(d)) with respect to such shares of fonix Common
Stock.
(e) Transfers of Ownership. At the Effective Time, the
stock transfer books of the AcuVoice shall be closed and there shall be no
further registration of transfers of AcuVoice Capital Stock thereafter on the
records of the AcuVoice. If any certificate for shares of fonix Common Stock
is to be issued in a name other than in which the AcuVoice Certificate
surrendered in exchange therefor is registered, it will be a condition of the
issuance thereof that the AcuVoice Certificate so surrendered will be properly
endorsed and otherwise in proper form for transfer and that the person
requesting such exchange will have paid to fonix or any agent designated by it
any transfer or other taxes required by reason of the issuance of a
certificate for shares of fonix Common Stock in any name other than that of
the registered holder of the AcuVoice Certificate surrendered, or established
to the satisfaction of fonix or any agent designated by it that such tax has
been paid or is not payable.
(f) Termination of Exchange Fund. Any portion of the
Exchange Fund which remains undistributed to the shareholders of AcuVoice one
(1) year after the Effective Time shall be delivered to fonix, upon demand,
and any shareholders of AcuVoice who have not previously complied with this
Section 1.7 shall thereafter look only to fonix for payment of their claim for
the Merger Consideration and any dividends or distributions with respect to
fonix Common Stock.
(g) No Liability. Notwithstanding anything to the contrary
in this Section 1.7, none of the Exchange Agent, the Surviving Corporation or
any party hereto shall be liable to any person for any amount properly paid to
a public official pursuant to any applicable abandoned property, escheat or
similar law.
(h) Dissenting Shares. The provisions of this Section 1.7
shall also apply to Dissenting Shares that lose their status as such, except
that the obligations of fonix under this Section 1.7 shall commence on the
date of loss of such status and the holder of such shares shall be entitled to
receive in exchange for such shares the Merger Consideration to which such
holder is entitled pursuant to Section 1.6 hereof.
(i) Escrow. As soon as practicable after the Effective
Time, and subject to and in accordance with the provisions of Section 8
hereof, fonix shall cause to be distributed to the Escrow Agent (as defined in
Section 8 hereof) a certificate or certificates representing 80,000 shares of
fonix Common Stock (which shall be registered in the name of the Escrow Agent
as nominee for the holders of AcuVoice Certificates canceled pursuant to this
Section 1.7). Such shares shall be beneficially owned by the Holders (as
defined in Section 6.15 below) on a pro rata basis and such shares shall be
held in escrow and shall be available to compensate fonix for certain damages
as provided in Section 8. To the extent not used for such purposes, such
shares shall be released, all as provided in Section 8 hereof.
1.8 No Further Ownership Rights in AcuVoice Common Stock. The
Merger Consideration delivered upon the surrender for exchange of shares of AcuV
oice Common Stock in accordance with the terms hereof (including any
dividends, distributions or cash paid in lieu of fractional shares) shall be
deemed to have been issued in full satisfaction of all rights pertaining to
such shares of AcuVoice Common Stock, and there shall be no further
registration of transfers on the records of the Surviving Corporation of
shares of AcuVoice Common Stock which were outstanding immediately prior to
the Effective Time. If, after the Effective Time, AcuVoice Certificates are
presented to the Surviving Corporation for any reason, they shall be canceled
and exchanged as provided in this Section 1.
1.9 Lost, Stolen or Destroyed Certificates. In the event any
AcuVoice Certificates shall have been lost, stolen or destroyed, the Exchange
Agent shall issue in exchange for such lost, stolen or destroyed AcuVoice
Certificates, upon the making of an affidavit of that fact by the holder
thereof such Merger Consideration (and dividends, distributions and cash in
lieu of fractional shares) as may be required pursuant to Section 1.6;
provided, however, that fonix may, in its discretion and as a condition
precedent to the issuance thereof, require the owner of such lost, stolen or
destroyed AcuVoice Certificates to deliver a bond in such sum as it may
reasonably direct as indemnity against any claim that may be made against
fonix, the Surviving Corporation or the Exchange Agent with respect to the
AcuVoice Certificates alleged to have been lost, stolen or destroyed.
1.10 Tax Consequences. It is intended by the parties hereto
that the Merger shall constitute a tax-free reorganization within the meaning
of Section 368(a) of the Code.
1.11 Taking of Necessary Action; Further Action. Each of fonix,
Merger Sub and AcuVoice will take all such reasonable and lawful action as may
be necessary or desirable in order to effectuate the Merger in accordance with
this Agreement as promptly as possible. If, at any time after the Effective
Time, any further action is necessary or desirable to carry out the purposes
of this Agreement and to vest the Surviving Corporation with full right, title
and possession to all assets, property, rights, privileges, powers and
franchises of AcuVoice and Merger Sub, the officers and directors of AcuVoice
and Merger Sub are fully authorized in the name of their respective
corporations or otherwise to take, and will take, all such lawful and
necessary action, so long as such action is not inconsistent with this
Agreement.
2. Conditions to the Merger.
2.1 Conditions to Obligations of Each Party to Effect the
Merger. The respective obligations of each party to this Agreement to
consummate and effect this Agreement and the transactions contemplated hereby
shall be subject to the satisfaction at or prior to the Effective Time of each
of the following conditions, any of which may be waived, in writing, by
agreement of all the parties hereto:
(a) Shareholder Approval. This Agreement and the Articles
of Merger shall be approved and adopted by the shareholders of the AcuVoice by
the requisite vote under applicable law and the AcuVoice's Articles of
Incorporation. Notwithstanding anything in this Agreement to the contrary,
the issuance of shares of fonix Common Stock, whether in the Merger or in
connection with the Merger or any transaction contemplated hereby, shall have
been approved by the stockholders of fonix if required by applicable law or by
any requirement of the National Association of Securities Dealers.
(b) No Injunctions or Restraints; Illegality. No temporary
restraining order, preliminary or permanent injunction or other order issued
by any court of competent jurisdiction or other legal or regulatory restraint
or prohibition preventing the consummation of the Merger shall be and remain
in effect, nor shall any proceeding brought by any administrative agency or
commission or other governmental authority or instrumentality, domestic or
foreign, seeking any of the foregoing be pending, which would have a Material
Adverse Effect (as defined in Section 9.2 below) on either fonix or on fonix
combined with the Surviving Corporation after the Effective Time, nor shall
there be any action taken, or any statute, rule, regulation or order enacted,
entered, enforced or deemed applicable to the Merger, which makes the
consummation of the Merger illegal. In the event an injunction or other order
shall have been issued, each party agrees to use its reasonable diligent
efforts to have such injunction or other order lifted.
(c) Governmental Approval. fonix, AcuVoice and Merger Sub
and their respective subsidiaries shall have timely obtained from each
Governmental Entity (as defined below) all approvals, waivers and consents, if
any, necessary for consummation of or in connection with the Merger and the
several transactions contemplated hereby, including such approvals, waivers
and consents as may be required under the Securities Act, under state Blue Sky
laws, and other filings and approvals relating to the Merger or affecting
Merger Sub's acquisition of AcuVoice or any of its properties if failure to
obtain such approval, waiver or consent would not have a Material Adverse
Effect on fonix or on fonix combined with the Surviving Corporation after the
Effective Time.
(d) Tax Opinions. AcuVoice and fonix shall each have
received substantially identical written opinions from their respective
counsel, Wilson, Sonsini, Goodrich & Rosati, Professional Corporation and
Durham, Evans, Jones & Pinegar, P.C., in form and substance reasonably
satisfactory to them to the effect that the Merger will constitute a
reorganization within the meaning of Section 368(a) of the Code. In rendering
such opinions, counsel may rely upon (and, to the extent reasonably required,
the parties and AcuVoice's shareholders shall make) reasonable representations
related thereto.
2.2 Additional Conditions to Obligations of AcuVoice. The
obligations of AcuVoice to consummate and effect this Agreement and the
transactions contemplated hereby shall be subject to the satisfaction at or
prior to the Effective Time of each of the following conditions, any of which
may be waived, in writing, by AcuVoice:
(a) Representations, Warranties and Covenants. (i) The
representations and warranties of fonix and Merger Sub in this Agreement shall
be true and correct in all material respects (except for such representations
and warranties that are qualified by their terms by a reference to materiality
which representations and warranties as so qualified shall be true in all
respects) on and as of the Effective Time as though such representations and
warranties were made on and as of such time and (ii) fonix and Merger Sub
shall have performed and complied in all material respects with all covenants,
obligations and conditions of this Agreement required to be performed and
complied with by them as of the Effective Time.
(b) Certificate of fonix. AcuVoice shall have been
provided with a certificate executed on behalf of fonix by its President and
its Chief Financial Officer to the effect that, as of the Effective Time:
(i) all representations and warranties made by fonix
and Merger Sub under this Agreement are true and complete in all material
respects; and
(ii) all covenants, obligations and conditions of this
Agreement to be performed by fonix and Merger Sub on or before such date have
been so performed in all material respects.
(c) Legal Opinion. AcuVoice shall have received a legal
opinion from Durham, Evans, Jones & Pinegar, fonix's legal counsel,
substantially in the form of Exhibit B-1 hereto.
(d) No Material Adverse Changes. There shall not have
occurred any material adverse change in the financial conditions, properties,
assets (including intangible assets), liabilities, business, operations or
results of operations of fonix and its subsidiaries, taken as a whole.
(e) Nasdaq Listing. The fonix Common Stock to be issued in
the merger shall have been authorized for listing on the Nasdaq SmallCap
Market upon official notice of issuance.
(f) Offer Letters. The employees of AcuVoice set forth on
Schedule 6.12 shall have accepted employment with Merger Sub pursuant to the
terms of an offer letter substantially in the form attached hereto as Exhibit
E, as applicable.
(g) Technology Purchase Option Agreement. fonix and E.
David Barton shall have executed and delivered a Technology Purchase Option
Agreement substantially in the form attached hereto as Exhibit F, as
applicable.
2.3 Additional Conditions to Obligations of fonix and Merger
Sub. The obligations of fonix and Merger Sub to consummate and effect this
Agreement and the transactions contemplated hereby shall be subject to the
satisfaction at or prior to the Effective Time of each of the following
conditions, any of which may be waived, in writing, by fonix:
(a) Representations, Warranties and Covenants: (i) The
representations and warranties of AcuVoice in this Agreement shall be true and
correct in all material respects (except for such representations and
warranties that are qualified by their terms by a reference to materiality
which representations and warranties as so qualified shall be true in all
respects) on and as of the Effective Time as though such representations and
warranties were made on and as of such time and (ii) AcuVoice shall have
performed and complied in all material respects with all covenants,
obligations and conditions of this Agreement required to be performed and
complied with by it as of the Effective Time.
(b) Certificate of AcuVoice. fonix shall have been
provided with a certificate executed on behalf of AcuVoice by its President
and Chief Financial Officer to the effect that, as of the Effective Time:
(i) all representations and warranties made by
AcuVoice under this Agreement are true and complete in all material respects
(except for such representations and warranties that are qualified by their
terms by a reference to materiality, which representations and warranties as
so qualified shall be true in all respects); and
(ii) all covenants, obligations and conditions of this
Agreement to be performed by AcuVoice on or before such date have been so
performed in all material respects.
(c) Third Party Consents. fonix shall have been finished
with evidence satisfactory to it of the consent or approval of those persons
whose consent or approval is required in connection with the Merger.
(d) Injunctions or Restraints on Conduct of Business. No
temporary restraining order, preliminary or permanent injunction or other
order issued by any court of competent jurisdiction or other legal or
regulatory restraint provision limiting or restricting fonix's conduct or
operation of the business of AcuVoice and its subsidiaries, following the
Merger shall be in effect, nor shall any proceeding brought by an
administrative agency or commission or other Governmental Entity, domestic or
foreign, seeking the foregoing be pending.
(e) Legal Opinion. fonix shall have received a legal
opinion from Wilson, Sonsini, Goodrich & Rosati, Professional Corporation,
AcuVoice's legal counsel, in substantially the form of Exhibit B-2.
(f) Escrow Agreement. fonix, Merger Sub, AcuVoice, Escrow
Agent and the Shareholders' Agent (as defined in Section 8 hereof) shall have
entered into an Escrow Agreement substantially in the form attached hereto as
Exhibit C.
(g) No Material Adverse Changes. In the sole judgment of
fonix, there shall not have occurred any material adverse change in the
financial condition, properties, assets (including intangible assets),
liabilities, business, operations or results of operations of AcuVoice, taken
as a whole.
(h) Affiliate Agreements. E. David Barton, John Y.
Mizutani and Jong S. Lee shall beneficially own at least a majority of the
outstanding AcuVoice Capital Stock and each shall have executed on the date
hereof and delivered to fonix an Affiliate Agreement substantially in the form
attached hereto as Exhibit D agreeing, inter alia, not to acquire more than
seven percent (7%), three percent (3%) and two percent (2%), respectively, of
fonix Common Stock and to vote in favor of the Merger at the time of any vote
by the shareholders of AcuVoice in connection with the Merger. As of the
Closing Date no party shall be in breach of any material term of the Affiliate
Agreement.
(i) Offer Letters. The employees of AcuVoice set forth on
Schedule 6.12 shall have accepted employment with Merger Sub pursuant to the
terms of an offer letter substantially in the form attached hereto as Exhibit
E, as applicable.
(j) Dissenters' Rights. Not more than five percent (5%) of
the AcuVoice Capital Stock outstanding immediately prior to the Effective Time
shall be eligible as Dissenters' Shares.
(k) Conversion of Preferred Stock. All shares of AcuVoice
Preferred Stock shall have converted into AcuVoice Common Stock in accordance
with AcuVoice's Articles of Incorporation prior to the Effective Time.
(l) Resignation of Directors. The directors of AcuVoice in
office immediately prior to the Effective Time shall have resigned as
directors of the Surviving Corporation effective as of the Effective Time.
(m) Tax Matters Agreement. The AcuVoice shareholders shall
have executed and delivered to fonix and AcuVoice a Tax Matters Agreement
substantially in the form attached to this Agreement as Exhibit G.
3. Representations and Warranties of AcuVoice. Except as disclosed
in a document of even date herewith and delivered by AcuVoice to fonix no
later than January 31, 1998, and referring to the representations and
warranties in this Agreement (the "AcuVoice Disclosure Schedule"), AcuVoice
represents and warrants to fonix and Merger Sub as follows, provided that
fonix shall have a period of two (2) business days after receipt of the
AcuVoice Disclosure Schedule within which to object to any of the contents
thereof, and in the event of such an objection, fonix shall have the right to
terminate this Agreement with no further obligation whatsoever to AcuVoice or
its shareholders upon written notice to AcuVoice, further provided, however,
that fonix shall have no right of termination under this Section 3 unless the
objection shall relate to a condition or event which reasonably would or could
have a Material Adverse Effect on AcuVoice, or on FAC or fonix if the
transaction is consummated:
3.1 Organization, Standing and Power. AcuVoice is a corporation
duly organized, validly existing and in good standing under the laws of its
jurisdiction of organization. AcuVoice has the corporate power to own its
properties and to carry on its business as now being conducted and is duly
qualified to do business and is in good standing in each jurisdiction in which
the failure to be so qualified and in good standing would have a Material
Adverse Effect on AcuVoice. AcuVoice has delivered a true and correct copy of
the Articles of Incorporation and Bylaws or other charter documents, as
applicable, of AcuVoice each as amended to date, to fonix. AcuVoice is not in
violation of any of the provisions of its Articles of Incorporation or Bylaws
or equivalent organizational documents. AcuVoice does not directly or
indirectly own any equity or similar interest in, or any interest convertible
or exchangeable or exercisable for, any equity or similar interest in, any
corporation, partnership, joint venture or other business association or
entity.
3.2 Authority. AcuVoice has all requisite corporate power and
authority to enter into this Agreement and to consummate the transactions
contemplated hereby. The execution and delivery of this Agreement and the
consummation of the transactions contemplated hereby have been duly authorized
by all necessary corporate action on the part of AcuVoice subject only to the
approval of the Merger by AcuVoice's shareholders as contemplated by Section
2.1(a). The affirmative vote of the holders of a majority of the shares of
the AcuVoice Common Stock and AcuVoice Preferred Stock voting as separate
classes outstanding on the record date for the written consent of shareholders
relating to this Agreement is the only vote of the holders of AcuVoice's
Capital Stock necessary under California Law to approve this Agreement and the
transactions contemplated hereby. The Board of Directors of AcuVoice has (i)
unanimously approved this Agreement and the Merger, (ii) determined that in
its opinion the Merger is in the best interests of the shareholders of
AcuVoice and is on terms that are fair to such shareholders and (iii)
recommended that the shareholders of AcuVoice approve this Agreement and the
Merger. This Agreement has been duly executed and delivered by AcuVoice and
constitutes the valid and binding obligation of AcuVoice enforceable against
AcuVoice in accordance with its terms, except that such enforceability may be
limited by bankruptcy, insolvency, moratorium or other similar laws affecting
or relating to creditors' rights generally, and is subject to general
principles of equity. The execution and delivery of this Agreement by
AcuVoice does not, and the consummation of the transactions contemplated
hereby will not conflict with, or result in any violation of, or default under
(with or without notice or lapse of time, or both), or give rise to a right of
termination, cancellation or acceleration of any material obligation or loss
of any material benefit under (i) any provision of the Articles of
Incorporation or Bylaws of AcuVoice, as amended, or (ii) any material
mortgage, indenture, lease, contract or other agreement or instrument, permit,
concession, franchise, license, judgment, order, decree, statute, law,
ordinance, rule or regulation applicable to AcuVoice or any of its properties
or assets. No consent, approval order or authorization of, or registration,
declaration or filing with, any court, administrative agency or commission or
other governmental authority or instrumentality ("Governmental Entity") is
required by or with respect to AcuVoice in connection with the execution and
delivery of this Agreement or the consummation of the transactions
contemplated hereby, except for (i) the filing of the Certificate of Merger,
together with the required officers' certificates, as provided in Section 1.2;
(ii) such consents, approvals, orders, authorizations, registrations,
declarations and filings as may be required under applicable state securities
laws and the securities laws of any foreign country; and (iii) such other
consents, authorizations, filings, approvals and registrations which, if not
obtained or made, would not have a Material Adverse Effect on AcuVoice and
wold not prevent, or materially alter or delay any of the transactions
contemplated by this Agreement.
3.3 Governmental Authority. AcuVoice has obtained each federal,
state, county, local or foreign governmental consent, license, permit, grant,
or other authorization of a Governmental Entity (i) pursuant to which AcuVoice
currently operates or holds any interest in any of its properties or (ii) that
is required for the operation of AcuVoice's business or the holding of any
such interest and all of such authorizations are in full force and effect
except where the failure to obtain or have any such authorizations could not
reasonably be expected to have a Material Adverse Effect on AcuVoice.
3.4 Capital Structure. The authorized capital stock of AcuVoice
consists of (i) 50,000,000 shares of AcuVoice Common Stock, of which there
were 8,881,920 shares issued and outstanding as of the close of business on
November 30, 1997 and (ii) 4,450,000 shares of AcuVoice Preferred Stock, of
which there were issued and outstanding as of that same date 2,000,000 shares
of Series A Preferred Stock, 50,000 shares of Series B Preferred Stock,
1,846,000 shares of Series C Preferred Stock, 200,000 shares of Series D
Preferred Stock and 200,000 shares of Series E Preferred Stock. All shares of
Preferred Stock are convertible into 4,608,049 shares of Common Stock. All
outstanding shares of AcuVoice Capital Stock are duly authorized, validly
issued, fully paid and non-assessable and are free of any liens or
encumbrances other than any liens or encumbrances created by or imposed upon
the holders thereof, and are not subject to preemptive rights or rights of
first refusal created by statute, the Articles of Incorporation or Bylaws of
AcuVoice or any agreement to which AcuVoice is a party or by which it is
bound. Except for the rights created pursuant to this Agreement, there are no
options, warrants, calls, rights, commitments or agreements of any character
to which AcuVoice is a party or by which it is bound obligating AcuVoice to
issue, deliver, sell, repurchase or redeem or cause to be issued, delivered,
sold, repurchased or redeemed, any shares of AcuVoice Capital Stock or
obligating AcuVoice to grant, extend, accelerate the vesting of, change the
price of, or otherwise amend or enter into any such option,. warrant, call,
right, commitment or agreement. There are no other contracts, commitments or
agreements relating to voting, purchase or sale of AcuVoice's capital stock
(i) between or among AcuVoice and any of its shareholders and (ii) to
AcuVoice's knowledge, between or among any of AcuVoice's shareholders, except
for the shareholders delivering the Affiliate Agreements (as defined below).
AcuVoice is not under any obligation to register under the Securities Act any
presently outstanding AcuVoice Capital Stock or any AcuVoice which may
subsequently be issued.
3.5 Financial Statements.
(a) AcuVoice has delivered to fonix its unaudited financial
statements for the fiscal year ended November 30, 1995 and November 30, 1996,
and its unaudited financial statements (balance sheet, statement of operations
and statement of cash flows) on a consolidated basis as at and for the ten
(10) month period ended September 30, 1997 (collectively, the "Financial
Statements"). The Financial Statements have been prepared in conformity with
generally accepted accounting principles ("GAAP") applied on a basis
consistent during the periods covered, present fairly the financial position
of AcuVoice and its results of operations for the periods covered thereby and
for purposes of this Agreement, the Financial Statements shall be deemed to
include any notes to such financial statements.
(b) AcuVoice has no liabilities or obligation, either
accrued, absolute, contingent or otherwise, which are material (according to
GAAP) and which have not been:
(i) reflected in the balance sheets to Financial
Statements of AcuVoice; or
(ii) specifically described in the AcuVoice Disclosure
Schedule furnished to fonix pursuant to this Agreement; or
(iii) incurred consistent with past practices, in or
as a result of the ordinary course of business since September 30, 1997.
(c) There are no pending, or to the best of AcuVoice's
knowledge, threatened claims (including, without limitation, product liability
claims) against or liabilities or obligations of AcuVoice which in the
aggregate are likely to result in a material reduction (for purposes of this
Section, a reduction in excess of 5% is deemed to be material) in the net
worth of AcuVoice from that shown in the Financial Statements or a material
charge against the earnings of AcuVoice.
(d) The present inventories of AcuVoice, in the judgment of
AcuVoice, are reasonable in relation to the present circumstances of its
business and all inventories shown on the Financial Statements or acquired
after the date of the Financial Statements but prior to the date of this
Agreement, are or will be set forth in the books of AcuVoice in accordance
with GAAP consistent with the method of treating said items in prior periods
and all of such inventories are and will be good and useful in the ordinary
course of business.
(e) All reserves established by AcuVoice with respect to
the assets of AcuVoice are adequate.
3.6 Absence of Certain Changes. Since September 30, 1997 (the
"AcuVoice Balance Sheet Date"), AcuVoice has conducted its business in the
ordinary course consistent with past practice and there has not occurred:
(i) any change, event or condition (whether or not
covered by insurance) that has resulted in, or might reasonably be expected to
result in, a Material Adverse Effect to AcuVoice;
(ii) any acquisition, sale or transfer of any material
asset of AcuVoice other than in the ordinary course of business and consistent
with past practice;
(iii) any change in accounting methods or practices
(including any change in depreciation or amortization policies or rates) by
AcuVoice or any revaluation by AcuVoice of any of its assets;
(iv) any declaration, setting aside, or payment of a
dividend or other distribution with respect to the AcuVoice Capital Stock or
any direct or indirect redemption, purchase or other acquisition by AcuVoice
of any of its shares of AcuVoice Capital Stock;
(v) any material contract entered into by AcuVoice,
other than in the ordinary course of business and as provided to fonix, or any
material amendment or termination of, or default under, any material contract
to which AcuVoice is a party or by which it is bound;
(vi) any amendment or change to the Articles of
Incorporation or Bylaws of AcuVoice;
(vii) any increase in or modification of the
compensation or benefits payable or to become payable by AcuVoice to any of
its directors, employees or independent contractors;
(viii) any alteration in any term of any AcuVoice
Capital Stock;
(ix) any (A) incurrence, assumption or guarantee by
AcuVoice of any debt for borrowed money; (B) issuance or sale of any
securities convertible into or exchangeable for debt securities of AcuVoice;
or (C) issuance or sale of options or other rights to acquire from AcuVoice,
directly or indirectly, debt securities of AcuVoice or any securities
convertible into or exchangeable for any such debt securities;
(x) any creation or assumption by AcuVoice of any
mortgage, pledge, security interest or lien or other encumbrance on any asset
(other than liens arising under existing lease financing arrangements or liens
arising in the ordinary course of AcuVoice's business which in the aggregate
are not material and liens for taxes not yet due and payable);
(xi) any making of any loan, advance or capital
contribution to or investment in any person other than travel loans or
advances made in the ordinary course of business of AcuVoice;
(xii) any entry into, amendment of, relinquishment,
termination or non-renewal by AcuVoice of any contract, lease transaction,
commitment or other right or obligation requiring aggregate payments by
AcuVoice in excess of $10,000 other than in the ordinary course of business;
(xiii) any transfer or grant of a right under, in or
to Intellectual Property, other than those transferred or granted in the
ordinary course of business consistent with past practice;
(xiv) any labor dispute, other than routine individual
grievances, or any activity or proceeding by a labor union or representative
thereof to organize any employees of AcuVoice; or
(xv) any negotiation or agreement by AcuVoice to do
any of the things described in the preceding clauses (i) through (xiv) (other
than negotiations with fonix and its representatives regarding the
transactions contemplated by this Agreement). At the Effective Time, there
will be no accrued but unpaid dividends on shares of AcuVoice Capital Stock.
3.7 Absence of Undisclosed Liabilities. AcuVoice has no
material obligations or liabilities of any nature (matured or unmatured, fixed
or contingent) other than (i) those set forth or adequately provided for in
the balance sheet for the period ended September 30, 1997 (the "AcuVoice
Balance Sheet"), (ii) those incurred in the ordinary course of business and
not required to be set forth in the AcuVoice Balance Sheet under GAAP, (iii)
those incurred in the ordinary course of business since the AcuVoice Balance
Sheet Date and consistent with past practice; and (iv) those incurred in
connection with the execution of this Agreement.
3.8 Litigation. There is no private or governmental action,
suit, proceeding, claim, arbitration or investigation pending before any
agency, court or tribunal, foreign or domestic, or, to the knowledge of
AcuVoice, threatened against AcuVoice or any of its properties or officers or
directors (in their capacities as such) that, individually or in the
aggregate, could reasonably be expected to have a Material Adverse Effect on
AcuVoice. There is no judgment, decree or order against AcuVoice, or, to the
knowledge of AcuVoice, any of its directors or officers (in their capacities
as such), that could prevent, enjoin, or materially alter or delay any of the
transactions contemplated by this Agreement, or that could reasonably be
expected to have a Material Adverse Effect on AcuVoice.
3.9 Restrictions on Business Activities. There is no agreement,
judgment, injunction, order or decree binding upon AcuVoice which has or could
reasonably be expected to have the effect of prohibiting or materially
impairing any current or future business practice of AcuVoice, any acquisition
of property by AcuVoice or the conduct of business by AcuVoice as currently
conducted or as proposed to be conducted by AcuVoice.
3.10 Intellectual Property.
(a) To the best of AcuVoice's knowledge, AcuVoice owns and
has good and marketable title to, or is licensed or otherwise possesses
legally enforceable rights to use (free and clear of any lien, encumbrance or
security interest), all patents, patent applications, trademarks, trade names,
service marks, copyrights (whether registered or unregistered), and any
applications therefor, maskworks, maskwork applications, net lists,
schematics, technology, know-how, trade secrets, inventory, ideas, algorithms,
processes, computer software programs or applications (in both source code and
object code form), client lists and tangible or intangible proprietary
information or material ("Intellectual Property") that are used or currently
proposed to be used in the business of AcuVoice as currently conducted or as
proposed to be conducted by AcuVoice, except to the extent that the failure to
have such rights has not had and would not reasonably be expected to have a
Material Adverse Effect on AcuVoice. AcuVoice is the exclusive owner of all
Intellectual Property.
(b) The AcuVoice Disclosure Schedule lists (i) all patents
and patent applications and all registered and unregistered trademarks, trade
names and service marks, registered and unregistered copyrights, and
maskworks, included in the Intellectual Property, including the jurisdictions
in which each such Intellectual Property right has been issued or registered
or in which any application for such issuance and registration has been filed,
(ii) all licenses, sublicenses and other agreements as to which AcuVoice is a
party and pursuant to which any person is authorized to use any Intellectual
Property, and (iii) all licenses, sublicenses and other agreements as to which
AcuVoice is a party and pursuant to which AcuVoice is authorized to use any
third party patents, trademarks, copyrights, know-how or other Intellectual
Property, including software ("Third Party Intellectual Property Rights")
which are incorporated in, are, or form a part of any AcuVoice product or are
used in the manufacture of any AcuVoice product.
(c) There has not been and there is not now any
unauthorized use, disclosure, infringement or misappropriation of any
Intellectual Property rights of AcuVoice, any trade secret material to
AcuVoice, or any Intellectual Property right of any third party to the extent
licensed by or through AcuVoice, by any third party, including any employee or
former employee of AcuVoice. AcuVoice has not entered into any agreement to
indemnify any other person against any charge of infringement of any
Intellectual Property, other than indemnification provisions contained in
sales agreements arising in the ordinary course of business. There are no
royalties, fees or other payments payable by AcuVoice to any person by reason
of the ownership, use, sale or disposition of Intellectual Property.
(d) AcuVoice is not, nor will it be as a result of the
execution and delivery of this Agreement or the performance of its obligations
under this Agreement, in breach of any license, sublicense or other agreement
relating to the Intellectual Property or Third Party Intellectual Property
Rights, the breach of which would have a Material Adverse Effect on AcuVoice.
(e) All patents, registered trademarks, service marks and
copyrights held by AcuVoice are valid and subsisting. AcuVoice is not
infringing, misappropriating or making unlawful use of, and has not received
any notice or any communication (in writing or otherwise) of any actual,
alleged, possible or potential infringement, misappropriation or unlawful use
of any proprietary asset owned or used by any third party. AcuVoice (i) has
not been sued in any suit, action or proceeding which involves a claim of
infringement of any patents, trademarks, service marks, copyrights or
violation of any trade secret or other proprietary right of any third party;
and (ii) has not brought any action, suit or proceeding for infringement of
Intellectual Property or breach of any license or agreement involving
Intellectual Property against any third party.
(f) All current and former officers, employees and
consultants of AcuVoice have executed and delivered to AcuVoice an agreement
(containing no exceptions or exclusions from the scope of its coverage)
regarding the protection of proprietary information and the assignment to
AcuVoice of any Intellectual Property arising from services performed for
AcuVoice by such persons, the form or forms of which have been supplied to
fonix and all current and former consultants and independent contractors to
AcuVoice involved in the development, modification, marketing and servicing of
AcuVoice's technology and/or software have executed and delivered to AcuVoice
an agreement (containing no exceptions or exclusions from the scope of its
coverage) in the form of which has been delivered to fonix. To AcuVoice's
knowledge, no employee or independent contractor of AcuVoice is in violation
of any term of any patent disclosure agreement or employment contract or any
other contract or agreement relating to the relationship of any such employee
or independent contractor with AcuVoice.
(g) AcuVoice has taken all commercially reasonable and
customary measures and precautions necessary to protect and maintain the
confidentiality of all Intellectual Property (except such Intellectual
Property the value of which would be unimpaired by public disclosure) and
otherwise to maintain and protect the full value of all proprietary assets.
All use, disclosure or appropriation of Intellectual Property not otherwise
protected by patents, patent applications or copyright ("Confidential
Information") owned by AcuVoice by or to a third party has been pursuant to
the terms of a written agreement between AcuVoice and such third party. All
use, disclosure or appropriation of Confidential Information not owned by
AcuVoice has been pursuant to the terms of a written agreement between
AcuVoice and the owner of such Confidential Information, or is otherwise
lawful.
(h) To AcuVoice's knowledge, no product liability claims
have been communicated in writing to or threatened against AcuVoice.
(i) A complete list of AcuVoice's proprietary software
("AcuVoice Software"), together with a brief description, is set forth in the
AcuVoice Disclosure Schedule. The AcuVoice Software conforms in all material
respects with any specification, documentation, performance standard,
representation or statement provided with respect thereto by or on behalf of
AcuVoice.
(j) No Intellectual Property is subject to any outstanding
order, judgment, decree, stipulation or agreement restricting in any manner
the licensing thereof by AcuVoice. AcuVoice has not entered into any
agreement to indemnify any other person against any charge of infringement of
any Intellectual Property. AcuVoice has not entered into any agreement
granting any third party the right to bring infringement actions with respect
to, or otherwise to enforce rights with respect to, any Intellectual
Property. AcuVoice has the exclusive right to file, prosecute and maintain
all applications and registrations with respect to Intellectual Property.
(k) AcuVoice entered into a License Agreement ("General
Magic License") with an effective date of September 23, 1997, with General
Magic, Inc. ("General Magic"), a copy of which is attached to the AcuVoice
Disclosure Schedule. AcuVoice represents and warrants that: (i) the Field of
Use as identified in the General Magic License is limited to use in General
Magic's Serengeti product, as currently defined by General Magic, as a
subscription based network service; (ii) the option granted in Paragraph 5 of
the General Magic License ("General Magic Option") for source code and all
source code documentation and license to use, reproduce, modify and create
derivative works from such source code and source code documentation and a
license to use the object code form of such derivative works is limited to use
in General Magic's Serengeti product, as currently defined by General Magic,
as a subscription based network service; and (iii) neither the General Magic
License nor the General Magic Option covers AcuVoice text-to-speech software
contained on any AcuVoice product other than Model AV2001, consisting of its
applicable syntax processor and mail-voice library of digitized sounds. Both
the General Magic License and the General Magic Option cover the current
AcuVoice text-to-speech software contained in the above-mentioned product,
Model AV2001 new releases, bug fixes and updates of that product.
3.11 Interested Party Transactions. AcuVoice is not indebted to
any director, officer, employee or agent of AcuVoice (except for amounts due
as normal salaries and bonuses and in reimbursement of ordinary expenses), and
no such person is indebted to AcuVoice. There have been no transactions
during the two year period ending on September 30, 1997 which would require
disclosure under Item 404 of Regulation S-K under the Securities Act.
3.12 Minute Books. The minute books of AcuVoice made available
to fonix contain a complete and accurate summary of all meetings of directors
and shareholders or actions by written consent since the time of incorporation
of AcuVoice through the date of this Agreement, and reflect all transactions
referred to in such minutes accurately in all material respects.
3.13 Complete Copies of Materials. AcuVoice has delivered or
made available true and complete copies of each document which has been
requested by fonix or its counsel in connection with their legal and
accounting review of AcuVoice.
3.14 Material Contracts. All the material contracts and
agreements to which AcuVoice is a party are listed in the AcuVoice Disclosure
Schedule. With respect to each agreement so listed: (i) the agreement is
legal, valid, binding and enforceable and in full force and effect with
respect to AcuVoice, and to AcuVoice's knowledge is legal, valid, binding,
enforceable and in full force and effect with respect to each other party
thereto, in either case subject to the effect of bankruptcy, insolvency,
moratorium or other similar laws affecting the enforcement of creditors'
rights generally and except as the availability of equitable remedies may be
limited by general principles of equity; (ii) the agreement will continue to
be legal, valid, binding and enforceable and in full force and effect
immediately following the Closing in accordance with the terms thereof as in
effect prior to the Closing, subject to the effect of bankruptcy, insolvency,
moratorium or other similar laws affecting the enforcement of creditors'
rights generally and except as the availability of equitable remedies may be
limited by general principles of equity; and (iii) neither the AcuVoice nor,
to AcuVoice's knowledge, any other party, is in breach or default, and no
event has occurred which with notice or lapse of time would constitute a
breach of default by AcuVoice or, to AcuVoice's knowledge, by any such other
party, or permit termination, modification or acceleration, under the
agreement. AcuVoice is not a party to any material oral contract, agreement
or other arrangement.
3.15 Accounts Receivable. Subject to any reserves set forth in
the Financial Statements, the accounts receivable shown on the Financial
Statements represent and will represent bona fide claims against debtors for
sales and other charges, are collectible in accordance with their terms at
their recorded amounts and are not subject to discount except for normal cash
and immaterial trade discounts. The amount carried for doubtful accounts and
allowances disclosed in the Financial Statements is sufficient to provide for
any losses which may be sustained on revaluation of the receivables.
3.16 Customers and Suppliers. As of the date hereof, no
customer which individually accounted for more than 5% of AcuVoice's gross
revenues during the 12 month period preceding the date hereof and no supplier
of AcuVoice, has canceled or otherwise terminated, or made any written threat
to AcuVoice to cancel or otherwise terminate its relationship with AcuVoice or
has at any time on or after December 31, 1997 decreased materially its
services or supplies to AcuVoice in the case of any such supplier, or its
usage of the services or products of AcuVoice in the case of such customer,
and to AcuVoice's knowledge, no such supplier or customer has indicated either
orally or in writing that it will cancel or otherwise terminate its
relationship with AcuVoice or to decrease materially its services or supplies
to AcuVoice or its usage of the services or products of AcuVoice, as the case
may be. AcuVoice has not knowingly breached, so as to provide a benefit to
AcuVoice that was not intended by the parties, any agreement with, or engaged
in any fraudulent conduct with respect to, any customer or supplier of
AcuVoice.
3.17 Employees and Consultants. The AcuVoice Disclosure
Schedule contains a list of the names of all employees and consultants of
AcuVoice, their respective salaries or wages, other compensation and dates of
employment and positions.
3.18 Title to Property. AcuVoice has good and marketable title
to all of its properties, interests in properties and assets, real and
personal, reflected in the AcuVoice Balance Sheet or acquired after the
AcuVoice Balance Sheet Date (except properties, interests in properties and
assets sold or otherwise disposed of since the AcuVoice Balance Sheet Date in
the ordinary course of business), or with respect to leased properties and
assets, valid leasehold interests therein, free and clear of all mortgages,
liens, pledges, charges or encumbrances of any kind or character, except (i)
the lien of current taxes not yet due and payable; (ii) such imperfections of
title, liens and easements as do not and will not materially detract from or
interfere with the use of the properties subject thereto or affected thereby,
or otherwise materially impair business operations involving such properties
and (iii) liens securing debt which is reflected on the AcuVoice Balance
Sheet. The plants, property and equipment of AcuVoice that are used in the
operations of its businesses are in all material respects in good operating
condition and repair, subject to normal wear and tear. All material
properties used in the operations of AcuVoice are reflected in the AcuVoice
Balance Sheet to the extent GAAP require the same to be reflected. All leases
to which AcuVoice is a party are in full force and effect and are valid,
binding and enforceable in accordance with their respective terms, except as
such enforceability may be limited by (i) bankruptcy laws and other similar
laws affecting creditors' rights generally and (ii) general principles of
equity, regardless of whether asserted in a proceeding in equity or at law.
True and correct copies of all such leases have been provided to fonix.
AcuVoice owns no real property. The AcuVoice Disclosure Schedule sets forth a
true and complete list of all real property leased by AcuVoice. Assuming the
due execution and delivery thereof by the other parties thereto, all such real
property leases are in full force and effect and are valid, binding and
enforceable in accordance with their respective terms, except as such
enforceability may be limited by (i) bankruptcy laws and other similar laws
affecting creditors' rights generally and (ii) general principles of equity,
regardless of whether asserted in a proceeding in equity or at law. True and
correct copies of all such real property leases have been provided to fonix.
3.19 Environmental Matters.
(a) The following terms shall be defined as follows:
(i) "Environmental Laws" shall mean any federal, state
or local laws, ordinances, codes, regulations, rules, policies and orders that
are intended to assure the protection of the environment, or that classify,
regulate, call for the remediation of, require reporting with respect to, or
list or define air, water, groundwater, solid waste, hazardous or toxic
substances, materials, wastes, pollutants, contaminants, or which are intended
to assure the safety of employees, workers or other persons, including the
public.
(ii) "Hazardous Materials' shall mean any toxic or
hazardous substance, material or waste or any pollutant or contaminant, or
infectious or radioactive substance or material, including without limitation,
those substances, materials and wastes defined in or regulated under any
Environmental Laws.
(b) AcuVoice is not and has not been in violation of any
Environmental Law relating to the properties or facilities of AcuVoice at
which any part of AcuVoice's business is or has been conducted. AcuVoice has
not used, generated, manufactured or stored on or under any part of its
properties or facilities at which any part of AcuVoice's business is or has
been conducted, or transported to or from any part thereof, any Hazardous
Materials in violation of any applicable Environmental Laws. There has not
been any presence, disposal, or release of any Hazardous Materials on, from or
under any part of AcuVoice's properties or facilities at which any part of
AcuVoice's business is or has been conducted. No civil, criminal or
administrative action, proceeding or investigation is pending against
AcuVoice, or to AcuVoice's knowledge, threatened against AcuVoice, and
AcuVoice is not aware of any facts or circumstances which could form the basis
for assertion of a claim or liability, regarding noncompliance with
Environmental Laws relating to the AcuVoice's business.
3.20 Taxes. As used in this Agreement, the terms "Tax" and,
collectively, "Taxes" mean all taxes, however denominated, including without
limitation any and all federal, state and local taxes of any country, or any
agency or political subdivision assessments and other governmental charges,
duties, impositions and liabilities, including without limitation taxes based
upon or measured by gross receipts, income, profits, sales, use, net worth,
capital, real or personal property, gains, occupation, and value added, ad
valorem, stamp, license, transfer, franchise, withholding, payroll, workers'
compensation, social security, disability, recapture, employment, unemployment
insurance and excise taxes, together with all interest, penalties and
additions imposed with respect to such amounts and any obligations under any
agreements or arrangements with any other person with respect to such amounts
and including without limitation any liability for taxes of a predecessor
entity.
(a) AcuVoice has prepared and timely filed all returns,
estimates, information statements, reports and related schedules required to
be filed with any taxing authority ("Returns") relating to any and all Taxes
concerning or attributable to AcuVoice or its operations or assets with
respect to Taxes for any period ending on or before the Closing Date and such
Returns are true and correct in all material respects and have been completed
in all material respects in accordance with applicable law or an adequate
reserve has been made for such Taxes on the AcuVoice Balance Sheet.
(b) AcuVoice, as of the Closing Date: (i) will have paid
all Taxes shown to be payable on such Returns covered by Section 3.20(a) and
(ii) will have withheld with respect to its employees all Taxes required to be
withheld.
(c) There is no Tax deficiency outstanding or assessed or,
to the best of AcuVoice's knowledge, proposed against AcuVoice, and there are
no substantial outstanding tax issues which, if audited, would create a tax
assessment, that is not reflected as a liability on the AcuVoice Balance Sheet
nor has AcuVoice executed any agreements or waivers extending any statute of
limitations on or extending the period for the assessment or collection of any
Tax.
(d) AcuVoice has no material liabilities for unpaid Taxes
that have not been accrued for or reserved on the AcuVoice Balance Sheet,
whether asserted or unasserted, contingent or otherwise.
(e) AcuVoice is not a party to any tax-sharing agreement or
similar arrangement with any other party, or any contractual obligation to pay
any Tax obligations of, or with respect to any transaction relating to, any
other person or to indemnify any other person with respect to any Tax.
(f) AcuVoice's Returns have never been audited by a
government or taxing authority, nor is any such audit in process or pending,
and AcuVoice has not been notified of any request for such an audit or other
examination.
(g) AcuVoice has never been a member of an affiliated group
of corporations filing a consolidated federal income tax return.
(h) AcuVoice is not aware of any plan or intention on the
part of its shareholders to engage in a sale or sales of fonix Common Stock to
be received pursuant to the Merger such that the aggregate fair market value,
as of the Effective Time, of the fonix Common Stock subject to such sales
would exceed fifty percent (50%) of the aggregate fair market value of all
shares of AcuVoice Capital Stock outstanding immediately prior to the
Effective Time. For purposes of this Section 3.20(h), the term "sale" shall
include any sale, exchange, transfer, distribution, redemption or reduction in
any way of the risk of ownership (by short sale or otherwise), or other
disposition, whether direct or indirect.
(i) AcuVoice has made available to fonix copies of all
Returns filed for all periods since its inception.
(j) AcuVoice has not filed any consent agreement under
Section 341(f) of the Code or agreed to have Section 341(f)(2) apply to any
disposition of assets owned by AcuVoice.
(k) AcuVoice has not been at any time a United States Real
Property Holding Corporation within the meaning of Section 897(c)(2) of the
Code.
(l) AcuVoice is not a party to any contract, agreement,
plan or arrangement, including but not limited to the provisions of this
Agreement, covering any employee or former employee of AcuVoice that,
individually or collectively, could give rise to the payment of any amount
that would not be deductible by AcuVoice or Merger Sub as an expense under
applicable law.
3.21 Employee Benefit Plans.
(a) The AcuVoice Disclosure Schedule lists, with respect to
AcuVoice and any trade or business (whether or not incorporated) which is
treated as a single employer with AcuVoice (an "ERISA Affiliate") within the
meaning of Section 414(b), (c), (m) or (o) of the Code, (i) all material
employee benefit plans (as defined in Section 3(3) of the employee Retirement
Income Security Act of 1974, as amended ("ERISA"), (ii) each loan to a
non-officer employee in excess of $10,000, loans to officers and directors and
any stock option, stock purchase, phantom stock, stock appreciation right, or
similar rights, supplemental retirement, severance, sabbatical, medical,
dental, vision care, disability, employee relocation, cafeteria benefit (Code
Section 125) or dependent care (Code Section 129), life insurance or accident
insurance plans, programs or arrangements, (iii) all bonus, pension, profit
sharing, savings, qualified or nonqualified deferred compensation or incentive
plans, programs or arrangements, (iv) other fringe or employee benefit plans,
programs or arrangements that apply to senior management of AcuVoice and that
do not generally apply to all employees, and (v) any current or former
employment or executive compensation or severance agreements, written or
otherwise, as to which unsatisfied obligations of AcuVoice of greater than
$10,000 remain for the benefit of or relating to, any present or former
employee, consultant or director of AcuVoice (together, the "AcuVoice Employee
Plans").
(b) AcuVoice has furnished to fonix a copy of each of the
AcuVoice Employee Plans and related plan documents (including trust documents,
insurance policies or contracts, employee booklets, summary plan descriptions
and other authorizing documents, and, to the extent still in its possession,
any material employee communications relating thereto) and has, with respect
to each AcuVoice Employee Plan which is subject to ERISA reporting
requirements, provided copies of the Form 5500 reports filed for the last
three plan years. Any AcuVoice Employee Plan intended to be qualified under
Section 401(a) of the Code has either obtained from the Internal Revenue
Service a favorable determination letter as to its qualified status under the
Code, including all amendments to the Code effected by the Tax Reform Act of
1986 and subsequent legislation, or has applied to the Internal Revenue
Service for such a determination letter prior to the expiration of the
requisite period under applicable Treasury Regulations or Internal Revenue
Service pronouncements in which to apply for such determination letter and to
make any amendments necessary to obtain a favorable determination, or has been
established under a standardized prototype plan for which an Internal Revenue
Service opinion letter has been obtained by the plan sponsor and is valid as
to the adopting employer. AcuVoice has also furnished fonix with the most
recent Internal Revenue Service determination or opinion letter issued with
respect to each such AcuVoice Employee Plan, and nothing has occurred since
the issuance of each such letter which could reasonably be expected to cause
the loss of the tax-qualified status of any AcuVoice Employee Plan subject to
Code Section 401(a).
(c) (i) None of the AcuVoice Employee Plans promises or
provides retiree medical or other retiree welfare benefits to any person; (ii)
there has been no "prohibited transaction," as such term is defined in Section
406 of ERISA and Section 4975 of the Code, with respect to any AcuVoice
Employee Plan, which could reasonably be expected to have, in the aggregate, a
Material Adverse Effect; (iii) each AcuVoice Employee Plan has been
administered in accordance with its terms and in compliance with the
requirements prescribed by any and all statutes, rules and regulations
(including ERISA and the Code), except as would not have, in the aggregate, a
Material Adverse Effect, and AcuVoice and each subsidiary or ERISA Affiliate
have performed all material obligations required to be performed by them
under, are not in any material respect in default under or violation of and
have no knowledge of any material default or violation by any other party to,
any of the AcuVoice Employee Plans; (iv) neither AcuVoice nor any ERISA
Affiliate is subject to any liability or penalty under Sections 4976 through
4980 of the Code or Title I of ERISA with respect to any of the AcuVoice
Employee Plans; (v) all material contributions required to be made by AcuVoice
or any ERISA Affiliate to any AcuVoice Employee Plan has been made on or
before their due dates and a reasonable amount has been accrued for
contributions to each AcuVoice Employee Plan for the current plan years; (vi)
with respect to each AcuVoice Employee Plan, no "reportable event" within the
meaning of Section 4043 of ERISA (excluding any such event for which the
thirty (30) day notice requirement has been waived under the regulations to
Section 4043 of ERISA) nor any event described in Section 4062, 4063 or 4041
or ERISA has occurred; and (vii) no AcuVoice Employee Plan is covered by, and
neither AcuVoice or any ERISA Affiliate has incurred or expects to incur any
liability under Title IV of ERISA or Section 412 of the Code. With respect to
each AcuVoice Employee plan subject to ERISA as either an employee pension
plan within the meaning of Section 3(2) of ERISA or an employee welfare
benefit plan within the meaning of Section 3(1) of ERISA, AcuVoice has
prepared in good faith and timely filed all requisite governmental reports
(which were true and correct as of the date filed) and has properly and timely
filed and distributed or posted all notices and reports to employees required
to be filed, distributed or posted with respect to each such AcuVoice Employee
Plan. No suit, administrative proceeding, action or other litigation has been
brought, or to the knowledge of AcuVoice is threatened, against or with
respect to any such AcuVoice Employee Plan, including any audit or inquiry by
the IRS or United States Department of Labor. Neither AcuVoice or other ERISA
Affiliate is a party to, or has made any contribution to or otherwise incurred
any obligation under, any "multiemployer plan as defined in Section 3(37) of
ERISA.
(d) With respect to each AcuVoice Employee Plan, AcuVoice
and each of its United States subsidiaries have complied with (i) the
applicable health care continuation and notice provisions of the Consolidated
Omnibus Budget Reconciliation Act of 1985 ("COBRA") and the proposed
regulations thereunder and (ii) the applicable requirements of the Family
Leave Act of 1993 and the regulations thereunder, except to the extent that
such failure to comply would not in the aggregate, have a Material Adverse
Effect.
(e) The consummation of the transactions contemplated by
this Agreement will not (i) entitle any current or former employee or other serv
ice provider of AcuVoice or any other ERISA Affiliate to severance benefits or
any other payment (including, without limitation, unemployment compensation,
golden parachute or bonus), except as expressly provided in this Agreement or
(ii) accelerate the time of payment or vesting of any such benefits, or
increase the amount of compensation due any such employee or service provider.
(f) There has been no amendment to, written interpretation
or announcement (whether or not written) by AcuVoice or any other ERISA
Affiliate relating to, or change in participation or coverage under, any
AcuVoice Employee Plan which would materially increase the expense of
maintaining such Plan above the level of expense incurred with respect to that
Plan for the most recent fiscal year included in AcuVoice's financial
statements.
3.22 Employee Matters. AcuVoice is in compliance with all
currently applicable laws and regulations respecting discrimination in
employment, terms and conditions of employment, wages, hours and occupational
safety and health and employment practices, except for such noncompliance as
has not and would not reasonably be expected to have had a Material Adverse
Effect on AcuVoice, and is not engaged in any unfair labor practice. There
are no pending claims against AcuVoice under any workers' compensation plan or
policy or for long term disability. AcuVoice has no material obligations
under COBRA with respect to any former employees or beneficiaries thereunder.
There are no proceedings pending or, to the knowledge of AcuVoice, threatened,
between AcuVoice and its employees or former employees, which proceedings have
or could reasonably be expected to have a Material Adverse Effect on
AcuVoice. AcuVoice is not a party to any collective bargaining agreement or
other labor union contract nor does AcuVoice know of any activities or
proceedings of any labor union to organize its employees. There has been no
claim against AcuVoice based on actual or alleged race, age, sex, disability
or other harassment or discrimination, or similar tortious conduct, nor, to
AcuVoice's knowledge, is there any basis for such claim. In addition,
AcuVoice has provided all employees with all relocation benefits, stock
options, bonuses and incentives, and all other compensation earned up through
the date of this Agreement.
3.23 Insurance. AcuVoice has policies of insurance and bonds of
the type and in amounts customarily carried by persons conducting businesses
or owning assets similar to those of AcuVoice. There is no material claim
pending under any of such policies or bonds as to which coverage has been
questioned, denied or disputed by the underwriters of such policies or bonds.
All premiums due and payable under all such policies and bonds have been paid
and AcuVoice is otherwise in compliance with the terms of such policies and
bonds. AcuVoice has no knowledge of any threatened termination of, or
material premium increase with respect to, any of such policies.
3.24 Compliance with Laws. AcuVoice has complied with, is not
in violation of and has not received any notices of violation with respect to,
any federal, state, local or foreign statute, law or regulation with respect
to the conduct of its business, or the ownership or operation of its business,
except for such violations or failures comply as could not be reasonably
expected to have a Material Adverse Effect on AcuVoice.
3.25 Brokers' and Finders' Fees. AcuVoice has not incurred, nor
will it incur, directly or indirectly, any liability for brokerage or finders'
fees or agents' commissions or investment bankers' fees or any similar charges
in connection with this Agreement or any transaction contemplated hereby.
3.26 Questionable Payments. Neither AcuVoice nor to its best
knowledge any director, officer or other employee of AcuVoice has: (i) made
any payments or provided services or other favors in the United States of
America or in any foreign country in order to obtain preferential treatment or
consideration by any Governmental Entity with respect to any aspect of the
business of AcuVoice; or (ii) made any political contributions which would not
be lawful under the laws of the United States and the foreign country in which
such payments were made. Neither AcuVoice nor to its best knowledge any
director, officer or other employee of AcuVoice nor, to the best knowledge of
AcuVoice, any customer or supplier of any of them has been the subject of any
inquiry or investigation by any Governmental Entity in connection with
payments or benefits or other favors to or for the benefit of any governmental
or armed services official, agent, representative or employee with respect to
any aspect of the business of AcuVoice or with respect to any political
contribution.
3.27 Disclosure. No representation or warranty made by AcuVoice
in this Agreement, nor any document, written information, statement, Financial
Statement, certificate, schedule or exhibit prepared and furnished or to be
prepared and furnished by AcuVoice or its representatives pursuant hereto or
in connection with the transactions contemplated hereby, including without
limitation the AcuVoice Disclosure Schedule, contains or will contain any
untrue statement of a material fact, or omits or will omit to state a material
fact necessary to make the statements or facts contained herein or therein not
misleading in light of the circumstances under which they were furnished. To
the best knowledge of AcuVoice after reasonable inquiry, there is no event,
fact or condition that has resulted in, or could reasonably be expected to
result in, a Material Adverse Effect that has not been set forth in this
Agreement or in the AcuVoice Disclosure Schedule.
4. Representations and Warranties of fonix and Merger Sub. Except as
disclosed in a document of even date herewith and delivered by fonix to
AcuVoice prior to the execution and delivery of this Agreement and referring
to the representations and warranties in this Agreement (the "fonix Disclosure
Schedule"), fonix and Merger Sub represent and warrant to AcuVoice as follows:
4.1 Organization, Standing and Power. Each of fonix and Merger
Sub is a corporation duly organized, validly existing and in good standing
under the laws of its jurisdiction of organization. Each of fonix and Merger
Sub has the corporate power to own its properties and to carry on its business
as now being conducted and as proposed to be conducted and is duly qualified
to do business and is in good standing in each jurisdiction in which the
failure to be so qualified and in good standing would have a Material Adverse
Effect on fonix. fonix has delivered a true and correct copy of the
Certificate of Incorporation, Articles of Incorporation and Bylaws or other
charter documents, as applicable, of fonix and Merger Sub, each as amended to
date, to AcuVoice. Neither fonix nor Merger Sub is in violation of any of the
provisions of its Certificate or Articles of Incorporation or Bylaws or
equivalent organizational documents.
4.2 Capital Structure. fonix has an authorized capitalization
consisting of 100,000,000 shares of Common Stock, par value $.0001 per share,
and 20,000,000 shares of Preferred Stock, par value $.0001 per shares. As of
December 31, 1997, fonix has issued and outstanding 43,079,177 shares of
Common Stock. 10,050,000 shares of Common Stock are subject to issuance upon
the conversion or exercise of presently issued and outstanding warrants and
options of fonix. [____________] shares of Common Stock are reserved for
issuance under fonix's existing stock option plans. 166,667 shares of Series
A Preferred Stock have been issued and 166,667 shares are outstanding. No
shares of Series B Convertible Preferred Stock are issued or outstanding.
187,500 shares of Series C Convertible Preferred Stock have been issued and
185,000 shares are outstanding. All of the shares of Common Stock and
Preferred Stock issued to date have been duly and validly authorized and
issued and are fully paid and non-assessable. Except as set forth above or as
disclosed in the fonix Disclosure Schedule, as of the date of this Agreement,
(i) there are no outstanding options, warrants, script, rights to subscribe
to, calls or commitments of any character whatsoever relating to, or
securities or rights convertible into, any shares of capital stock of fonix or
any of its subsidiaries, or contracts, commitments, understandings or
arrangements by which fonix or any of its subsidiaries is or may become bound
to redeem or issue additional shares of capital stock of fonix or any of its
subsidiaries or options, warrants, scrip, rights to subscribe to calls or
commitments of any character whatsoever relating, or securities or rights
convertible into, any shares of capital stock of fonix or any of its
subsidiaries, (ii) there are no outstanding debt securities and (iii) there
are no agreements or arrangements under which fonix or any of its subsidiaries
is obligated to register the sale of any of their securities under the
Securities Act. Except as disclosed in the fonix Disclosure Schedule, there
are no securities or instruments containing any anti-dilution, right of first
refusal, preemptive rights or similar provisions that will be triggered by the
issuance of the Shares as described in this Agreement. Upon issuance of the
shares of fonix Common Stock to be issued pursuant to the Merger, such
securities will be duly and validly issued, fully paid and non-assessable.
4.3 Authority. fonix and Merger Sub have all requisite
corporate power and authority to enter into this Agreement and to consummate
the transactions contemplated hereby. The execution and delivery of this
Agreement and the consummation of the transactions contemplated hereby have
been duly authorized by all necessary corporate action on the part of fonix
and Merger Sub. This Agreement has been duly executed and delivered by fonix
and Merger Sub and constitutes the valid and binding obligations of fonix and
Merger Sub. The execution and delivery of this Agreement do not and the
consummation of the transactions contemplated hereby will not conflict with,
or result in any violation of, or default under (with or without notice or
lapse of time, or both), or give rise to a right of termination, cancellation
or acceleration of any material obligation or loss of a material benefit under
(i) any provision of the Certificate or Articles of Incorporation or Bylaws of
fonix or any of its subsidiaries, as amended, or (ii) any material mortgage,
indenture, lease, contract or other agreement or instrument permit,
concession, franchise, license, judgment, order, decree, statute, law,
ordinance, rule or regulation applicable to fonix or any of its subsidiaries
or their properties or assets. No consent approval, order or authorization of
or registration, declaration or filing with, any Governmental Entity, is
required by or with respect to fonix or any of its subsidiaries in connection
with the execution and delivery of this Agreement by fonix and Merger Sub or
the consummation by fonix and Merger Sub of the transactions contemplated
hereby, except for (i) the filing of the Certificate of Merger, together with
the required officers' certificates, as provided in Section 1.2, (ii) the
filing of a Form 8-K with the Securities and Exchange Commission ("SEC") and
Nasdaq Stock Market within 15 days after the Closing Date, (iii) any filings
as may be required under applicable state securities laws and the securities
laws of any foreign country, (iv) the filing with the Nasdaq SmallCap Market
of a Notification Form of Listing of Additional Shares with respect to the
shares of fonix Common Stock issuable upon conversion of the AcuVoice Common
Stock in the Merger, and (v) such other consents, authorizations, filings,
approvals and registrations which, if not obtained or made, would not have a
Material Adverse Effect on fonix and would not prevent, materially alter or
delay any of the transactions contemplated by this Agreement.
4.4 SEC Documents; Financial Statements. fonix has furnished to
AcuVoice a true and complete copy of each statement, report, registration
statement (with the prospectus in the form filed pursuant to Rule 424(b) of
the Securities Act), definitive proxy statement, and other filing filed with
the SEC by fonix since December 31, 1995, and, prior to the Effective Time,
fonix will have furnished AcuVoice with true and correct copies of any
additional documents filed with the SEC by fonix prior to the Effective Time
(collectively, the "fonix SEC Documents"). In addition, fonix has made
available to AcuVoice all material exhibits to the fonix SEC Documents filed
prior to the date hereof and will promptly make available to AcuVoice all
material exhibits to any additional fonix SEC Documents filed prior to the
Effective Time. All documents required to be filed as exhibits to the fonix
SEC Documents have been so filed, and all material contracts so filed as
exhibits are in full force and effect except those which have expired in
accordance with their terms, and neither fonix nor any of its subsidiaries is
in default thereunder. As of their respective filing dates, the fonix SEC
Documents complied in all material respects with the requirements of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the
Securities Act and none of the fonix SEC Documents contained any untrue
statement of a material fact or omitted to state a material fact required to
be stated therein or necessary to make the statements made therein, in light
of the circumstances in which they were made, not misleading, except to the
extent corrected by a subsequently filed fonix SEC Document prior to the date
hereof. The financial statements of fonix, including the notes thereto,
included in the fonix SEC Documents (the "fonix Financial Statements"),
complied as to form in all material respects with applicable accounting
requirements and with the published rules and regulations of the SEC with
respect thereto as of their respective dates, and have been prepared in
accordance with GAAP applied on a basis consistent throughout the periods
indicated and consistent with each other (except as may be indicated in the
notes thereto or, in the case of unaudited statements included in Quarterly
Reports on Form 10-Q or Form 10-QSB, as permitted by Form 10-Q or Form 10-QSB
of the SEC). The fonix Financial Statements fairly present the consolidated
financial condition and operating results of fonix and its subsidiaries at the
dates and during the periods indicated therein (subject, in the case of
unaudited statements, to normal, recurring year-end adjustments). There has
been no material change in fonix accounting policies except as described in
the notes to the fonix Financial Statement. Since December 31, 1996, no event
has occurred that would have required the filing of any report that otherwise
would have been included among the SEC Documents and for which an appropriate
report was not filed.
4.5 Absence of Certain Changes. Since September 30, 1997 (the
"fonix Balance Sheet Date"), except as described in the fonix SEC Documents,
fonix has conducted its business in the ordinary course consistent with past
practice and there has not occurred: (i) any change, event or condition
(whether or not covered by insurance) that has resulted in, or might reasonably
be expected to result in, a Material Adverse Effect to fonix; (ii) any
acquisition, sale or transfer of any material asset of fonix or any of its
subsidiaries other than in the ordinary course of business and consistent with
past practice; (iii) any material change in accounting methods or practices
(including any change in depreciation or amortization policies or rates) by
fonix or any revaluation by fonix of any of its assets; (iv) any declaration,
setting aside, or payment of a dividend or other distribution with respect to
the shares of fonix, or any direct or indirect redemption, purchase or other
acquisition by fonix of any of its shares of capital stock; (v) any material
contract entered into by fonix, other than in the ordinary course of business
and as provided to AcuVoice or any material amendment or termination of, or
default under, any material contract to which fonix is a party or by which it
is bound; (vi) any amendment or change to fonix's Certificate of Incorporation
or Bylaws; or (vii) any negotiation or agreement by fonix or any of its
subsidiaries to do any of the things described in the preceding clauses (i)
through (vi) (other than negotiations with AcuVoice and its representatives
regarding the transactions contemplated by this Agreement).
4.6 Absence of Undisclosed Liabilities. fonix has no material
obligations or liabilities of any nature (matured or unmatured, fixed or
contingent) other than (i) those set forth or adequately provided for in the
Balance Sheet included in fonix's Quarterly Report on Form 10-Q for the period
ended September 30, 1997 (the "fonix Balance Sheet"), (ii) those incurred in
the ordinary course of business and not required to be set forth in the fonix
Balance Sheet under GAAP, and (iii) those incurred in the ordinary course of
business since the fonix Balance Sheet Date and consistent with past practice.
4.7 Litigation. Except as described in the fonix SEC Documents,
there is no private or governmental action, suit, proceeding, claim,
arbitration or investigation pending before any agency, court or tribunal,
foreign or domestic, or, to the knowledge of fonix or any of its subsidiaries,
threatened against fonix or any of its subsidiaries or any of their respective
properties or any of their respective officers or directors (in their
capacities as such) that, individually or in the aggregate, could reasonably
be expected to have a Material Adverse Effect on fonix. There is no judgment,
decree or order against fonix or any of its subsidiaries or, to the knowledge
of fonix or any of its subsidiaries, any of their respective directors or
officers (in their capacities as such) that could prevent, enjoin, or
materially alter or delay any of the transactions contemplated by this
Agreement, or that could reasonably be expected to have a Material Adverse
Effect on fonix.
4.8 Governmental Authorization. fonix and each of its
subsidiaries have obtained each federal, state, county, local or foreign
governmental consent, license, permit, grant, or other authorization of a
Governmental Entity (i) pursuant to which fonix or any of its subsidiaries
currently operates or holds any interest in any of its properties or (ii) that
is required for the operation of fonix's or any of its subsidiaries' business
or the holding of any such interest ((i) and (ii) herein collectively called
"fonix Authorizations"), and all of such fonix Authorizations are in full
force and effect, except where the failure to obtain or have any of such fonix
Authorizations could not reasonably be expected to have a Material Adverse
Effect on fonix.
4.9 Broker's and Finders' Fees. fonix has not incurred, nor
will it incur, directly or indirectly, any liability for brokerage or finders'
fees or agents' commissions or investment bankers' fees or any similar charges
in connection with this Agreement or any transaction contemplated hereby.
4.10 Interim Operations of Merger Sub. Merger Sub was formed
solely for the purpose of engaging in the transactions contemplated by this
Agreement, has engaged in no other business activities and has conducted its
operations only as contemplated by this Agreement.
4.11 Post-Merger Operations of Merger Sub. fonix has no present
plan or intention to liquidate Merger Sub; to merge Merger Sub with and into
another corporation; to sell or otherwise dispose of the stock of Merger Sub;
or to cause Merger Sub to sell or otherwise dispose of any of the assets of
AcuVoice acquired in the transaction, except for dispositions made in the
ordinary course of business or transfers described in Section 368(a)(2)(C) of
the Code. fonix intends that following the Merger, Merger Sub will continue
the historic business of AcuVoice or use a significant portion of AcuVoice's
business assets in a business.
4.12 Representations Complete. None of the representations or
warranties made by fonix or Merger Sub herein or in any Schedule hereto, or in
the fonix Disclosure Schedule, or certificate furnished by fonix or Merger Sub
pursuant to this Agreement, or the fonix SEC Documents, or any written
statement furnished to AcuVoice pursuant hereto or in connection with the
transactions contemplated hereby, when all such documents are read together in
their entirety, contains or will contain at the Effective Time any untrue
statement of material fact or omits or will omit at the Effective Time to
state any material fact necessary in order to make the statements contained
herein or therein, in the light of the circumstances under which made, not
misleading; provided, however, that for purposes of this representation, any
document attached hereto and any document specifically referenced in the fonix
Disclosure Schedule as a "Superseding Document" (even if not attached hereto)
that provides information inconsistent with or in addition to any other
written statement furnished to AcuVoice in connection with the transactions
contemplated hereby, shall be deemed to supersede any other document or
written statement furnished to AcuVoice with respect to such inconsistent or
additional information, and further provided that, with regard to the fonix
SEC Documents and the fonix Financial Statements, the foregoing representation
and warranty is made only as of the date of filing of such fonix SEC Documents
and fonix Financial Statements and each report or statement filed under the
Exchange Act is deemed and understood to be a Superceding Document with
respect to reports previously filed under the Exchange Act.
5. Conduct Prior to the Effective Time.
5.1 Conduct of Business of AcuVoice and fonix. During the
period from the date of this Agreement and continuing until the earlier of the
termination of this Agreement or the Effective Time, each of AcuVoice and
fonix agrees (except to the extent expressly contemplated by this Agreement or
as consented to in writing by the other), to carry on its and its
subsidiaries' business in the usual regular and ordinary course in
substantially the same manner as heretofore conducted; to pay and to cause its
subsidiaries to pay debts and Taxes when due subject (i) to good faith
disputes over such debts or Taxes and (ii) in the case of Taxes of AcuVoice,
to fonix's consent to the filing of material Tax Returns if applicable; to pay
or perform other obligations when due, and to use all reasonable efforts to
preserve intact its present business organizations, keep available the
services of its and its subsidiaries' present officers and key employees and
preserve its and its subsidiaries' relationships with customers, suppliers,
distributors, licensors, licensees, and others having business dealings with
it or its subsidiaries, to the end that its and its subsidiaries' goodwill and
ongoing businesses shall be unimpaired at the Effective Time. Each of
AcuVoice and fonix agrees to promptly notify the other of (x) any event or
occurrence not in the ordinary course of its or its subsidiaries' business,
and of any event which could have a Material Adverse Effect and (y) any
material change in its capitalization as set forth in Sections 3.4 and 4.2,
respectively. Without limiting the foregoing, except as expressly
contemplated by this Agreement or the AcuVoice Disclosure Schedule or the
fonix Disclosure Schedule, neither AcuVoice nor fonix, respectively, shall do,
cause or permit any of the following, or allow, cause or permit any of its
subsidiaries to do, cause or permit any of the following, without the prior
written consent of the other:
(a) Charter Documents. Cause or permit any amendments to
its Articles or Certificate of Incorporation or Bylaws;
(b) Dividends; Changes in Capital Stock. Declare or pay
any dividends on or make any other distributions (whether in cash, stock or
property) in respect of any of its capital stock, or split, combine or
reclassify any of its capital stock or issue or authorize the issuance of any
other securities in respect of, in lieu of or in substitution for shares of
its capital stock, or repurchase or otherwise acquire, directly or indirectly,
any shares of capital stock except from former employees, directors and
consultants in accordance with agreements providing for the repurchase of
shares in connection with any termination of service to it or its
subsidiaries;
(c) Other. Take, or agree in writing or otherwise to take,
any of the actions described in Sections 5.1(a) through (b) above, or any
action which would cause a material breach of its representations or
warranties contained in this Agreement or prevent it from materially
performing or cause it not to materially perform its covenants hereunder;
5.2 Conduct of Business of AcuVoice. During the period from the
date of this Agreement and continuing until the earlier of the termination of
this Agreement or the Effective Time, except as expressly contemplated by this
Agreement or the AcuVoice Disclosure Schedule, AcuVoice shall not do, cause or
permit any of the following, without the prior written consent of fonix:
(a) Material Contracts. Enter into any material contract
or commitment, or violate, amend or otherwise modify or waive any of the terms
of any of its material contracts, other than in the ordinary course of
business consistent with past practices.
(b) Issuance of Securities. Issue, deliver or sell or
authorize or propose the issuance, delivery or sale of, or purchase or propose
the purchase of, any shares of its capital stock or securities convertible
into, or subscriptions, rights, warrants or options to acquire, or other
agreements or commitments of any character obligating it to issue any such
shares or other convertible securities;
(c) Intellectual Property. Transfer to any person or
entity any rights to its Intellectual Property other than in the ordinary
course of business consistent with past practice;
(d) Exclusive Rights. Enter into or amend any agreements
pursuant to which any other party is granted exclusive marketing or other
exclusive rights of any type or scope with respect to any of its products or
technology;
(e) Dispositions. Sell, lease, license or otherwise
dispose of or encumber any of its properties or assets which are material
individually or in the aggregate, to its business, except in the ordinary
course of business consistent with past practice;
(f) Indebtedness. Incur any indebtedness for borrowed
money or guarantee any such indebtedness or issue or sell any debt securities
or guarantee any debt securities of others;
(g) Agreements. Enter into, terminate or amend, in a
manner which will adversely affect the business of AcuVoice (i) any agreement
involving an obligation to pay or the right to receive $10,000 or more, (ii)
any agreement relating to the license, transfer or other disposition or
acquisition of intellectual property rights or rights to market or sell
AcuVoice products, or (iii) any other agreement which is material to the
business or prospects of AcuVoice;
(h) Payment of Obligations. Pay, discharge or satisfy in
an amount in excess of $10,000 in the aggregate, any claim, liability or
obligation (absolute, accrued, asserted or unasserted, contingent or
otherwise) arising other than in the ordinary course of business, other than
the payment, discharge or satisfaction of liabilities reflected or reserved
against in the AcuVoice Financial Statements;
(i) Capital Expenditures. Make any capital expenditures,
capital additions or capital improvements except in the ordinary course of
business and consistent with past practice;
(j) Insurance. Materially reduce the amount of any
material insurance coverage provided by existing insurance policies;
(k) Termination or Waiver. Terminate or waive any right of
substantial value, other than in the ordinary course of business;
(l) Employee Benefit Plans; New Hires; Pay Increases.
Adopt or amend any employee benefit or stock purchase or option plan, or hire
any new employee or employees, pay any special bonus or special remuneration
(except payments made pursuant to written agreements outstanding on the date
hereof), or increase the salaries or wage rates of its employees except in the
ordinary course of business in accordance with its standard past practice;
(m) Severance Arrangements. Grant any severance or
termination pay (i) to any director or officer or (ii) to any other employee
except (A) payments made pursuant to written agreements outstanding on the
date hereof or (B) grants which are made in the ordinary course of business in
accordance with its standard past practice;
(n) Lawsuits. Commence a lawsuit other than (i) for the
routine collection of bills, (ii) in any cases where it in good faith
determines that failure to commence suit would result in the material
impairment of a valuable aspect of its business, provided that it consults
with fonix prior to the filing of such a suit, or (iii) for a breach of this
Agreement;
(o) Acquisitions. Acquire or agree to acquire by merging
or consolidating with, or by purchasing a substantial portion of the assets
of, or by any other manner, any business or any corporation, partnership,
association or other business organization or division thereof or otherwise
acquire or agree to acquire any assets which are material individually or in
the aggregate, to its business;
(p) Taxes. Other than in the ordinary course of business
make or change any material election in respect of Taxes, adopt or change any
accounting method in respect of Taxes, file any material Tax Return or any
amendment to a material Tax Return, enter into any closing agreement, settle
any material claim or assessment in respect of Taxes, or consent to any
extension or waiver of the limitation period applicable to any material claim
or assessment in respect of Taxes;
(q) Revaluation. Revalue any of its assets, including
without limitation writing down the value of inventory or writing off notes or
accounts receivable other than in the ordinary course of business; or
(r) Other. Take or agree in writing or otherwise to take,
any of the actions described in Sections 5.2(a) through (q) above, or any
action which would cause a material breach of its representations or
warranties contained in this Agreement or prevent it from materially
performing or cause it not to materially perform its covenants hereunder.
5.3 No Solicitation.
(a) From and after the date of this Agreement until the
Effective Time, AcuVoice shall not, directly or indirectly through any
officer, director, employee, representative or agent of AcuVoice or otherwise,
(i) solicit, initiate, or encourage any inquiries or proposals that
constitute, or could reasonably be expected to lead to, a proposal or offer
for a merger, consolidation, share exchange, business combination, sale of all
or substantially all assets, sale of shares of capital stock or similar
transactions involving AcuVoice other than the transactions contemplated by
this Agreement (any of the foregoing inquiries or proposals being referred to
in this Agreement as an "Acquisition Proposal"), (ii) engage or participate in
negotiations or discussions concerning, or provide any nonpublic information
to any person or entity relating to, any Acquisition Proposal, or (iii) agree
to, enter into, accept, approve or recommend any Acquisition Proposal.
(b) AcuVoice shall notify fonix immediately (and no later
than 24 hours) after receipt by AcuVoice (or its advisors) of any Acquisition
Proposal or any request for nonpublic information in connection with an
Acquisition Proposal or for access to the properties, books or records of
AcuVoice by any person or entity that informs AcuVoice that it is considering
making, or has made, an Acquisition Proposal. Such notice shall be made
orally and in writing and shall indicate in reasonable detail the identity of
the offeror and the terms and conditions of such proposal, inquiry or contact.
6. Additional Agreements.
6.1 Preparation of Solicitation Statement.
(a) As soon as practicable after the execution of this
Agreement, AcuVoice and fonix shall jointly prepare a solicitation statement
for the solicitation of approval of the shareholders of AcuVoice describing
this Agreement, the Certificate of Merger and the transactions contemplated
hereby and thereby. The information supplied by AcuVoice for inclusion in the
solicitation statement to be sent to the shareholders of AcuVoice shall not,
on the date the solicitation statement is first mailed to AcuVoice's
shareholders or at the Effective Time, contain any statement which, at such
time, is false or misleading with respect to any material fact, or omit to
state any material fact necessary in order to make the statements made
therein, in light of the circumstances under which they are made, not false or
misleading, or omit to state any material fact necessary to correct any
statement in any earlier communication which has become false or misleading.
Notwithstanding the foregoing, AcuVoice makes no representation, warranty or
covenant with respect to any information supplied by fonix or Merger Sub which
is contained in any of the foregoing documents. The information supplied by
fonix for inclusion in the solicitation statement shall not, on the date the
solicitation statement is first mailed to AcuVoice's shareholders, nor at the
Effective Time, contain any statement which, at such time, is false or
misleading with respect to any material fact, or omit to state any material
fact necessary in order to make the statements therein, in light of the
circumstances under which it is made, not false or misleading; or omit to
state any material fact necessary to correct any statement in any earlier
communication which has become false or misleading. Notwithstanding the
foregoing, fonix and Merger Sub make no representation, warranty or covenant
with respect to any information supplied by AcuVoice which is contained in any
of the foregoing documents.
(b) The solicitation statement shall constitute a
disclosure document for the offer and issuance of shares of fonix Common Stock
to be received by the holders of AcuVoice Capital Stock in the Merger. fonix
and AcuVoice shall each use reasonable commercial efforts to cause the
solicitation statement to comply with applicable federal and state securities
laws requirements. Each of fonix and AcuVoice agrees to provide promptly to
the other such information concerning its business and financial statements
and affairs as, in the reasonable judgment of the providing party or its
counsel, may be required or appropriate for inclusion in the solicitation
statement or in any amendments or supplements thereto, and to cause its
counsel and auditors to cooperate with the other's counsel and auditors in the
preparation of the solicitation statement. AcuVoice will promptly advise
fonix, and fonix will promptly advise AcuVoice, in writing if at any time
prior to the Effective Time either AcuVoice or fonix shall obtain knowledge of
any facts that might make it necessary or appropriate to amend or supplement
the solicitation statement in order to make the statements contained or
incorporated by reference therein not misleading or to comply with applicable
law. The solicitation statement shall contain the recommendation of the Board
of Directors of AcuVoice that the AcuVoice shareholders approve the Merger and
this Agreement and the conclusion of the Board of Directors that the terms and
conditions of the Merger are fair and reasonable to the shareholders of
AcuVoice. Anything to the contrary contained herein notwithstanding, AcuVoice
shall not include in the solicitation statement any information with respect
to fonix or its affiliates or associates, the form and content of which
information shall not have been approved by fonix prior to such inclusion.
6.2 Approval of Shareholders. AcuVoice shall promptly after the
date hereof take all action necessary in accordance with California Law and
its Articles of Incorporation and Bylaws to obtain the written consent of the
AcuVoice Shareholders approving the Merger as soon as practicable. Subject to
Section 6.1, AcuVoice shall use its best efforts to solicit from shareholders
of AcuVoice written consents in favor of the Merger and shall take all other
action necessary or advisable to secure the vote or consent of shareholders
required to effect the Merger.
6.3 Sale of Shares Pursuant to Section 4(2) of the Securities
Act. The parties hereto acknowledge and agree that the shares of fonix Common
Stock issuable to the AcuVoice shareholders pursuant to Section 1.6 hereof
shall be issued and sold pursuant to the exemption available by Section 4(2)
of the Securities Act and the rules and regulations promulgated thereunder
including, without limitation, Regulations S and D, and as such, the fonix
Common Stock, shall constitute "restricted securities" within the Securities
Act. The certificates of fonix Common Stock shall bear the legends set forth
in Section 1.6(g).
6.4 Access to Information.
(a) AcuVoice shall afford fonix and its accountants,
counsel and other representatives, reasonable access during normal business
hours during the period prior to the Effective Time to (i) all of AcuVoice's
properties, books, contracts, commitments and records (including Tax Returns
filed and those in preparation), and (ii) all other information concerning the
business, properties and personnel of AcuVoice as fonix may reasonably
request. AcuVoice agrees to provide to fonix and its accountants, counsel and
other representatives copies of internal financial statements promptly upon
request. AcuVoice further agrees to provide fonix with the following
information as soon as practicable following the date of this Agreement:
(i) The jurisdiction in which each AcuVoice
Intellectual Property Right has been issued or registered or in which an
application for such issuance or registration has been filed, including the
respective registration or application numbers;
(ii) all licenses, sublicenses and other agreements as
to which AcuVoice is a party and pursuant to which AcuVoice or any other
person is authorized to use any AcuVoice Intellectual Property Right,
including the identity of all parties thereto, a description of the nature and
subject matter thereof, all material rights, restrictions, conditions, or
other terms pertaining to each AcuVoice Intellectual Property Right, the
applicable royalty or other consideration and the term thereof, and including
the extent to which rights with respect to AcuVoice Intellectual Property
Rights survive termination or expiration thereof (copies of all licenses,
sublicenses, and other agreements identified pursuant to this clause (a)(ii)
have previously been delivered by AcuVoice to fonix);
(iii) all parties to whom AcuVoice has delivered
copies of AcuVoice source code, whether pursuant to an escrow agreement or
otherwise, or parties who have the right to receive such source code; and
(iv) a true and complete list of all real property
owned or leased by AcuVoice and the aggregate rental or other fee payable
under any such lease.
fonix shall afford AcuVoice and its accountants, counsel and other
representatives, reasonable access during normal business hours during the
period prior to the Effective Time to (i) all of fonix's and its subsidiaries'
properties, books, contracts, commitments and records, and (ii) all other
information concerning the business, properties and personnel of fonix and its
subsidiaries as AcuVoice may reasonably request. fonix agrees to provide to
AcuVoice and its accountants, counsel and other representatives copies of
internal financial statements promptly upon request.
(b) Subject to compliance with applicable law, from the
date hereof until the Effective Time, each of fonix and AcuVoice shall confer
on a regular and frequent basis with one or more representatives of the other
party to report operational matters of materiality and the general status of
ongoing operations.
(c) No information or knowledge contained in any
investigation pursuant to this Section 6.4 shall affect or be deemed to modify
any representation or warranty contained herein or the conditions to the
obligations of the parties to consummate the Merger.
6.5 Confidentiality. The parties acknowledge that fonix and
AcuVoice have previously executed a non-disclosure agreement contained in
Paragraph 10 of the Letter of Intent dated November 12, 1997 (the
"Confidentiality Agreement"), which Confidentiality Agreement is hereby
incorporated herein by reference and shall continue in full force and effect
in accordance with its terms.
6.6 Public Disclosure. Unless otherwise permitted by this
Agreement, fonix and AcuVoice shall consult with each other before issuing any
press release or otherwise making any public statement or making any other
public (or non-confidential) disclosure (whether or not in response to an
inquiry) regarding the terms of this Agreement and the transactions
contemplated hereby, and neither shall issue any such press release or make
any such statement or disclosure without the prior approval of the other
(which approval shall not be unreasonably withheld), except as may be required
by law or by obligations pursuant to any listing agreement with any national
securities exchange or with the Nasdaq Stock Market.
6.7 Affiliate Agreement. AcuVoice shall use its best efforts,
on behalf of fonix and pursuant to the request of fonix, to cause E. David
Barton, John Y. Mizutani and Jong S. Lee, to execute on the date hereof and
deliver to fonix an Affiliate Agreement substantially in the form attached
hereto as Exhibit D, concurrently with the execution of this Agreement and in
any event prior to the time that the solicitation statement is mailed to the
shareholders of AcuVoice.
6.8 Legal Requirements. Each of fonix, Merger Sub and AcuVoice
will, and will cause their respective subsidiaries to, take all reasonable
actions necessary to comply promptly with all legal requirements which may be
imposed on them with respect to the consummation of the transactions
contemplated by this Agreement and will promptly cooperate with and furnish
information to any party hereto necessary in connection with any such
requirements imposed upon such other party in connection with the consummation
of the transactions contemplated by this Agreement and will take all
reasonable actions necessary to obtain (and will cooperate with the other
parties hereto in obtaining) any consent, approval, order or authorization of
or any registration, declaration or filing with, any Governmental Entity or
other person, required to be obtained or made in connection with the taking of
any action contemplated by this Agreement.
6.9 Blue Sky Laws. fonix shall take such steps as may be
necessary to comply with the securities and blue sky laws of all jurisdictions
which are applicable to the issuance of the fonix Common Stock in connection
with the Merger. AcuVoice shall use its best efforts to assist fonix as may
be necessary to comply with the securities and blue sky laws of all
jurisdictions which are applicable in connection with the issuance of fonix
Common Stock in connection with the Merger.
6.10 Escrow Agreement. On or before the Effective Time, fonix,
Merger Sub, Escrow Agent and the Shareholders' Agent (as defined in Section
8.7 hereto) will execute the Escrow Agreement contemplated by Section 8 in the
form attached hereto as Exhibit C ("Escrow Agreement").
6.11 Listing of Additional Shares. Prior to the Effective Time,
fonix shall file with the Nasdaq SmallCap Market a Notification Form for
Listing of Additional Shares with respect to the shares of fonix Common Stock
issuable upon conversion of the AcuVoice Common Stock in the Merger.
6.12 Employees. Set forth in Schedule 6.12 is a list of
employees of AcuVoice to whom Merger Sub will make an offer to enter into
employment pursuant to offer letters substantially in the form attached hereto
as Exhibit E and with salaries equal to these set forth opposite each
employee's name on Schedule 6.12. AcuVoice shall use its best efforts (i) to
cause each of such employees set forth in Schedule 6.12 to execute an offer
letter in the form attached hereto as Exhibit E, and (ii) to cause each other
AcuVoice employee to execute and deliver to Merger Sub an offer letter and an
Assignment of Inventions and Non-Disclosure Agreement in the forms provided by
Merger Sub.
6.13 Reorganization. fonix and AcuVoice shall each use its best
efforts to cause the business combination to be effected by the Merger to be
qualified as a "reorganization" described in Section 368(a) of the Code.
6.14 Expenses. Subject to the letter agreement between fonix
and AcuVoice dated November 12, 1997, which is hereby incorporated by
reference, whether or not the Merger is consummated, all costs and expenses
incurred in connection with this Agreement and the transactions contemplated
hereby shall be paid by the party incurring such expense. The parties hereto
agree that counsel to AcuVoice shall be paid via wire transfer all amounts
owed to them at the Closing.
6.15 Registration of Shares Issued in the Merger.
(a) For purposes of this Agreement, "Registrable Shares"
shall mean the shares of fonix Common Stock issued in the Merger, including
any and all Escrowed Shares (as defined below), but excluding shares of fonix
Common Stock issued in the Merger that have been sold or otherwise transferred
by the holders of AcuVoice Capital Stock who initially received such shares in
the Merger (collectively, the "Holders"); provided, however, that a
distribution of shares of fonix Common Stock issued in the Merger without
additional consideration to underlying beneficial owners (such as the general
and limited partners, shareholders or trust beneficiaries of a Holder) shall
not be deemed such a sale or transfer for purposes of this Section 6.15 and
such underlying beneficial owners shall be entitled to the same rights under
this Section 6.15 as the initial Holder from which the Registrable Shares were
received and shall be deemed a Holder for the purposes of this Section 6.15.
(b) In case fonix shall receive from a majority of the
Holders a written request that fonix effect any registration, qualification or
compliance with respect to shares of Registrable Securities, fonix will:
(i) promptly give written notice of the proposed
registration, qualification or compliance to all other Holders; and
(ii) as soon as practicable, use its best efforts to
effect such registration, qualification or compliance (including, without
limitation, appropriate qualification under applicable blue sky or other state
securities laws and appropriate compliance with applicable regulations issued
under the Securities Act and any other governmental requirements or
regulations) as may be so requested and as would permit or facilitate the sale
and distribution of all or such portion of such Registrable Securities as are
specified in such request, together with all or such portion of the
Registrable Securities of any Holder or Holders joining in such request as are
specified in a written request received by fonix within 20 days after receipt
of such written notice from fonix.
(c) Notwithstanding the foregoing, fonix shall not be
obligated to take any action pursuant to Section 6.15(b):
(i) in any particular jurisdiction in which fonix
would be required to execute a general consent to service of process in
effecting such registration, qualification or compliance, unless fonix is
already subject to service in such jurisdiction and except as may be required
by the Securities Act;
(ii) prior to twelve months after the Effective Time;
(iii) during the period starting with the date sixty
(60) days prior to fonix's estimated date of filing of, and ending on the date
ninety (90) days (or such longer period of time as required by any underwriter
participating in such offer of fonix's securities) immediately following the
effective date of, any registration statement pertaining to securities of
fonix (other than a registration of securities in a Rule 145 transaction or
with respect to an employee benefit plan), provided that fonix is actively
employing in good faith all reasonable efforts to cause such registration
statement to become effective; or
(iv) if fonix has previously effected one (1) such
registration.
Subject to the foregoing clauses (i) through (iv), fonix shall file a
registration statement covering the Registrable Securities so requested to be
registered as soon as practicable after receipt of the request or requests of
a majority of the Holders.
(d) The costs and expenses to be borne by fonix for
purposes of this Section 6.15 shall include, without limitation, printing
expenses, legal fees and disbursements of counsel for fonix, "blue sky"
expenses, accounting fees and filing fees, but shall not include underwriting
commissions or similar charges, legal fees and disbursements of counsel for
the selling Holders. All expenses of any registered offering not otherwise
borne by fonix shall be borne pro rata among the Selling Holders (and fonix
and other Holders selling securities in the offering) on the basis of the
number of shares registered.
(e) To the fullest extend permitted by law, fonix will
indemnify and hold harmless each selling Holder, each underwriter of fonix
Common Stock being sold by such Holders pursuant to this Section 6.15 and each
person, if any, who controls any such Holder or underwriter within the meaning
of the Securities Act or the Exchange Act against all actions, claims, losses,
damages, liabilities and expenses to which they or any of them become subject
under the Securities Act, the Exchange Act or under any other statute or at
common law or otherwise and, except as hereinafter provided, will promptly
reimburse each such Holder, each such underwriter and each such controlling
person, if any, for any legal or other expenses reasonably incurred by them or
any of them in connection with investigating or defending any actions whether
or not resulting in any liability, insofar as such losses, claims, damages,
expenses, liabilities or actions arise out of or are based upon any untrue
statement or alleged untrue statement of material fact in any registration
statement and any prospectus filed pursuant to Section 6.15(b) or 6.15(c) or
any post-effective amendment thereto or arise out of or are based upon any
omission or alleged omission to state a material fact required to be stated
therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading or any violation by
fonix of any rule or regulation promulgated under the Securities Act or the
Exchange Act applicable to fonix and relating to action or inaction required
by fonix in connection with such registration; provided, however, that fonix
shall not be liable to any such Holder, underwriter or controlling person in
respect of any claims, losses, damages, liabilities and expenses resulting
from any untrue statement or alleged untrue statement, or omission or alleged
omission made in reliance upon and in conformity with information furnished in
writing to fonix by such Holder or underwriter specifically for use in
connection with such registration statement and prospectus or post-effective
amendment.
(f) To the fullest extent permitted by law, each selling
Holder of Registrable Shares registered in accordance with Section 6.15(b) or
6.15(c) will indemnify fonix, each person, if any, who controls fonix within
the meaning of the Securities Act or the Exchange Act, each director of fonix
and each officer of fonix who signs the registration statement and each
underwriter of fonix Common Stock against any actions, claims, losses,
damages, liabilities and expenses to which they or any of them may become
subject under the Securities Act, the Exchange Act or under any other statute
or at common law or otherwise, and will promptly reimburse fonix and each such
director, officer, underwriter or controlling person for any legal or other
expenses reasonably incurred by them or any of them in connection with
investigating or defending any actions whether or not resulting in any
liability, insofar as such losses, claims, damages, expenses, liabilities or
actions arise out of or are based upon any untrue statement or alleged untrue
statement of a material fact in any registration statement and any prospectus
filed pursuant to Section 6.15(b) or 6.15(c) or any post-effective amendment
thereto, or any omission or alleged omission to state a material fact required
to be stated therein or necessary to make the statements therein, in light of
the circumstances under which they were made, not misleading, which untrue
statement or alleged untrue statement or omission or alleged omission was made
in reliance upon and in conformity with information furnished in writing to
fonix by such Holder or underwriter specifically for use in connection with
such registration statement, or any violation by such Holder of any rule or
regulation promulgated under the Securities Act or the Exchange Act applicable
to such Holder and relating to action or inaction required by such Holder in
connection with sales of securities covered by such registration, prospectus
or post-effective amendment; provided, however, that the obligations of each
such selling Holder hereunder shall be limited to an amount equal to the gross
proceeds to such Holder from the sale of such Holder's Registrable Shares as
contemplated herein.
(g) Each person entitled to indemnification under this
Section 6.15 (an "Indemnified Person") shall give notice to the party required
to provide indemnification (the "Indemnifying Person") promptly after such
Indemnified Person has actual knowledge of any claim as to which indemnity may
be sought and shall permit the Indemnifying Person to assume the defense of
any such claim and any litigation resulting therefrom, provided that counsel
for the Indemnifying Person who conducts the defense of such claim or any
litigation resulting therefrom shall be approved by the Indemnified Person
(whose approval shall not unreasonably be withheld), and the Indemnified
Person may participate in such defense at such party's expense (unless the
Indemnified Person has reasonably concluded that there may be a conflict of
interest between the Indemnifying Person and the Indemnified Person in such
action, in which case the fees and expenses of counsel for the Indemnified
Person shall be at the expense of the Indemnifying Person), and provided
further that the failure of any Indemnified Person to give notice as provided
herein shall not relieve the Indemnifying Person of its obligations under this
Section 6.15 except to the extent the Indemnifying Person is materially
prejudiced thereby. No Indemnifying Person, in the defense of any such claim
or litigation, shall (except with the consent of each Indemnified Person)
consent to entry of any judgment or enter into any settlement that does not
include as an unconditional term thereof the giving by the claimant or
plaintiff to such Indemnified Person of a release from all liability in
respect to such claim or litigation. Each Indemnified Person shall furnish
such information regarding itself or the claim in question as an Indemnifying
Person may reasonably request in writing and as shall be reasonably required
in connection with the defense of such claim and litigation resulting
therefrom.
(h) In order to provide for just and equitable contribution
to joint liability under the Securities Act in any case in which fonix or any
Holder makes a claim for indemnification pursuant to this Section 6.15 but it
is judicially determined (by the entry of a final judgment or decree by a
court of competent jurisdiction and the expiration of time to appeal or the
denial of the last right of appeal) that such indemnification may not be
enforced in such case notwithstanding that this Section 6.15 provides for
indemnification, in such case, then fonix and such Holder will contribute to
the aggregate losses, claims, damages or liabilities to which they may be
subject (after contribution from others) in such proportion as is appropriate
to reflect the relative fault of fonix on the one hand and of the Holder on
the other in connection with the statements or omission which resulted in such
losses, claims, damages or liabilities, as well as any other relevant
equitable considerations or, if the allocation provided herein is not
permitted by applicable law, in such proportion as shall be appropriate to
reflect the relative benefits received by fonix and any Holder of Registrable
Shares from the offering of the securities covered by such Registration
Statement. The relative fault of fonix on the one hand and of the Holder on
the other shall be determined by reference to, among other things, whether the
untrue or alleged untrue statement of a material fact or omission or alleged
omission to state a material fact relates to information supplied by fonix on
the one hand or by the Holder on the other, and each party's relative intent,
knowledge, access to information and opportunity to correct or prevent such
statement or omission; provided, however, that, in any such case no person or
entity guilty of fraudulent misrepresentation within the meaning of Section
11(f) of the Securities Act will be entitled to contribution from any person
or entity who was not guilty of such fraudulent misrepresentation.
(i) "Market Stand-Off" Agreement. In connection with a
public offering of securities by fonix pursuant to Section 6.15, each holder
who participates in the registration statement filed under the Securities Act
for such offering will not, to the extent requested in good faith by an
underwriter of securities of fonix, sell or otherwise transfer or dispose of
any Registrable Securities included in such registration statement (other than
to donees or partners of the Holder who agree to be similarly bound) for up to
that period of time, not to exceed one hundred eighty (180) days (the "Market
Stand-Off Period"), following the effective date of such registration
statement of fonix filed under the Securities Act as is requested by the
managing underwriter(s) of such offering; provided that the officers and
directors of fonix who own stock of fonix also agree to such restrictions. In
order to enforce the foregoing covenant, fonix may impose stop transfer
instructions with respect to the Registrable Securities of each such holder
(and the shares or securities of every other person subject to the foregoing
restriction) until the end of such period.
(j) Termination of fonix's Obligations. fonix will have no
obligations pursuant to this Section 6.15 hereof with respect to Registrable
Securities held by a Holder if in the opinion of counsel to fonix at the time
of filing a registration statement such Holder may sell all of such Holder's
Registrable Securities in any single three (3)-month period without
registration under the Securities Act pursuant to Rule 144.
6.16 Reasonable Commercial Efforts and Further Assurances. Each
of the parties to this Agreement shall use reasonable commercial efforts to
effectuate the transactions contemplated hereby and to fulfill and cause to be
fulfilled the conditions to closing under this Agreement. Each party hereto,
at the reasonable request of another party hereto, shall execute and deliver
such other instruments and do and perform such other acts and things as may be
necessary or desirable for effecting completely the consummation of this
Agreement and the transactions contemplated hereby.
7. Termination; Amendment and Waiver.
7.1 Termination. This Agreement may be terminated at any time
prior to the Effective Time (with respect to Section 7.1(b) through Section
7.1(d), by written notice by the terminating party to the other party):
(a) by the mutual written consent of fonix and AcuVoice;
(b) by either fonix or AcuVoice if the Merger shall not
have been consummated by March 28, 1998, provided, however, that the right to
terminate this Agreement under this Section 7.1(b) shall not be available to
any party whose failure to fulfill any obligation under this Agreement has
been the cause of or resulted in the failure of the Merger to occur on or
before such date;
(c) by either fonix or AcuVoice if a court of competent
jurisdiction or other Governmental Entity shall have issued a nonappealable
final order, decree or ruling or taken any other action, in each case having
the effect of permanently restraining, enjoining or otherwise prohibiting the
Merger, except, if the party relying on such order, decree or ruling or other
action has not complied with its obligations under this Agreement;
(d) by fonix, if there has been a breach of any of
AcuVoice's representations, warranties or covenants, which breach (i) causes
the conditions set forth in Section 2.1(a), (b) or (c) or 2.3(a) or (b) not to
be satisfied and (ii) shall not have been cured within ten (10) business days
following receipt by AcuVoice of written notice of such breach from fonix; or
(e) by AcuVoice, if there has been a breach of any of
fonix's representations, warranties or covenants which breach (i) causes the
conditions set forth in Section 2.2(a) or (b) not to be satisfied and (ii)
shall not have been cured within ten (10) business days following receipt by
fonix of written notice of such breach from AcuVoice.
7.2 Effect of Termination.
(a) In the event of termination of this Agreement as
provided in Section 7.1(a), (b), (c) or (e), there shall be no liability or
obligation on the part of fonix, AcuVoice, Merger Sub or their respective
officers, directors, or stockholders, except (i) to the extent that such
termination results from the willful breach by a party of any of its
representations, warranties or covenants set forth in this Agreement and (ii)
the provisions of Section 6.5 shall remain in full force and effect and
survive any termination of this Agreement.
(b) In the event of termination of this Agreement as
provided in Section 7.1(d), and in addition to any remedies, rights and/or
causes of action arising from the breach by AcuVoice of any of its
representations, warranties and covenants set forth in this Agreement, in
connection with such termination by fonix, AcuVoice shall return to fonix
$400,000 of the $500,000 earnest money previously delivered by fonix to
AcuVoice pursuant to that certain letter of intent between fonix and AcuVoice
dated November 12, 1997, and do so within ten (10) business days after the
event of termination provided in Section 7.1(d), together with interest
thereon at the rate of 18% per annum for every day after the tenth (10th)
business day in which AcuVoice refuses or fails to return all or part of said
$400,000; provided that the provisions of Section 6.5 shall remain in full
force and effect and survive any termination of this Agreement.
7.3 Amendment. This Agreement may be amended by the parties
hereto, by action taken or authorized by their respective Boards of
Directors. This Agreement may not be amended except by an instrument in
writing signed on behalf of each of the parties hereto.
7.4 Extension; Waiver. At any time prior to the Effective Time,
the parties hereto, by action taken or authorized by their respective Boards
of Directors, may, to the extent legally allowed, (i) extend the time for the
performance of any of the obligations or other acts of the other parties
hereto, (ii) waive any inaccuracies in the representations and warranties
contained herein or in any document delivered pursuant hereto and (iii) waive
compliance with any of the agreements or conditions contained herein. Any
agreement on the part of a party hereto to any such extension or waiver shall
be valid only if set forth in a written instrument signed on behalf of such
party.
8. Escrow and Indemnification.
8.1 Escrow Fund
(a) At the Closing, 80,000 shares of fonix Common Stock
(the "Escrow Shares") shall be registered in the name of, and be deposited
with Durham, Evans, Jones & Pinegar, P.C. (or other institution selected by
fonix with the reasonable consent of AcuVoice) as escrow agent (the "Escrow
Agent"), such deposit to constitute the Escrow Fund and to be governed by the
terms set forth herein and in the Escrow Agreement attached hereto as Exhibit
C. The Escrow Fund shall be available to compensate fonix pursuant to the
indemnification obligations of the shareholders of AcuVoice as set forth in
Section 8.2. In the event fonix issues any Additional Escrow Shares (as
defined below), such shares will be issued in the name of the Escrow Agent and
delivered to the Escrow Agent in the same manner as the Escrow Shares
delivered at the Closing.
(b) Except for dividends paid in stock declared with
respect to the Escrow Shares ("Additional Escrow Shares"), which shall be
treated pursuant to Section 8.l(a) hereof, any cash dividends, dividends
payable in securities or other distributions of any kind made in respect of
the Escrow Shares will be delivered to the shareholders of AcuVoice on a pro
rata basis. Each shareholder of AcuVoice will have voting rights with respect
to the Escrow Shares deposited in the Escrow Fund with respect to such
shareholder so long as such Escrow Shares are held in escrow, and fonix will
take all reasonable steps necessary to allow the exercise of such rights.
While the Escrow Shares remain in the Escrow Agent's possession pursuant to
this Agreement, the shareholders of AcuVoice will retain and will be able to
exercise all other incidents of ownership of said Escrow Shares which are not
inconsistent with the terms and conditions of this Agreement.
8.2 Indemnification.
(a) Survival of Warranties. All representations and
warranties made by AcuVoice or E. David Barton herein, or in any certificate,
schedule or exhibit delivered pursuant hereto, shall survive the Closing and
continue in full force and effect until the first anniversary of the Closing
Date (sometimes referred to herein as the "Termination Date").
(b) Subject to the limitations set forth in this Section 8,
the shareholders of AcuVoice will indemnify and hold harmless fonix and the
Surviving Corporation and their respective officers, directors, agents,
attorneys and employees, and each person, if any, who controls or may control
fonix or the Surviving Corporation within the meaning of the Securities Act
(hereinafter referred to individually as an "Indemnified Person" and
collectively as "Indemnified Persons") from and against any and all losses,
costs, damages, liabilities and expenses arising from claims, demands,
actions, causes of action, including, without limitation, legal fees
(collectively, "Damages") arising out of any misrepresentation or breach of or
default in connection with any of the representations, warranties, covenants
and agreements given or made by AcuVoice or E. David Barton in this Agreement,
the AcuVoice Disclosure Schedules or any exhibit, schedule or other instrument
made or given in connection with the execution and delivery of this
Agreement. fonix and its affiliates shall act in good faith and in a
commercially reasonable manner to mitigate any Damages they may suffer. The
sole recourse and maximum indemnification available hereunder of the
Indemnified Persons shall be the Escrow Fund.
(c) Nothing in this Agreement shall limit the liability in
amount or otherwise of AcuVoice or its shareholders with respect to fraud,
criminal activity or intentional breach of any covenant contained in this
Agreement.
8.3 Escrow Period; Release from Escrow.
(a) The Escrow Period shall terminate upon the expiration
of twelve months after the Effective Time; provided, however, that a portion
of the Escrow Fund, which, in the reasonable judgment of fonix, subject to the
objection of the Shareholders' Agent and the subsequent arbitration of the
matter in the manner provided in Section 8.6 hereof, is necessary to satisfy
any unsatisfied claims specified in any Officer's Certificate theretofore
delivered to the Escrow Agent prior to termination of the Escrow Period with
respect to facts and circumstances existing prior to expiration of the Escrow
Period, shall remain in the Escrow Fund until such claims have been resolved.
(b) Within three (3) business days after the Termination
Date (the "Release Date"), the Escrow Agent shall release from escrow to the
shareholders of AcuVoice their pro rata portion of the Escrow Shares and
Additional Escrow Shares less with respect to each such shareholder the number
of Escrow Shares and Additional Escrow Shares with a value (as determined
pursuant to Section 8.4) equal to (A) such shareholder's pro rata portion of
any liability delivered to fonix in accordance with Section 8.4 in
satisfaction of indemnification claims by Indemnified Persons and (B) such
shareholder's pro rata portion of any liability subject to delivery to
Indemnified Persons in accordance with Section 8.3(a) with respect to any
pending but unresolved indemnification claims of Indemnified Persons. Any
Escrow Shares and Additional Escrow Shares held as a result of clause (B)
shall be released to the shareholders of AcuVoice or released to fonix (as
appropriate) promptly upon resolution of each specific indemnification claim
involved. Escrow Shares and Additional Escrow Shares shall be released to the
respective shareholders of AcuVoice in proportion to their respective
ownership interest in AcuVoice immediately prior to the Effective Time. fonix
will take such action as may be necessary to cause such certificates to be
issued in the names of the appropriate persons. Certificates representing
Escrow Shares and Additional Escrow Shares so issued that are subject to
resale restrictions under applicable securities laws will bear a legend to
that effect. No fractional shares shall be released and delivered from Escrow
to the shareholders of AcuVoice. In lieu of any fraction of an Escrow Share
to which a AcuVoice shareholder would otherwise be entitled, such holder will
receive from fonix an amount of cash (rounded to the nearest whole cent) equal
to the product of such fraction multiplied by the Indemnification Price (as
defined below).
(c) No Escrow Shares or Additional Escrow Shares or any
beneficial interest therein may be pledged, sold, assigned or transferred,
including by operation of law, by any shareholder of AcuVoice or be taken or
reached by any legal or equitable process in satisfaction of any debt or other
liability of any such shareholder, prior to the delivery to such shareholder
of his pro rata portion of the Escrow Fund by the Escrow Agent as provided
herein.
(d) The Escrow Agent is hereby granted the power to effect
any transfer of Escrow Shares contemplated by this Agreement. fonix will
cooperate with the Escrow Agent in promptly issuing stock certificates to
effect such transfers.
8.4 Claims upon Escrow Fund. Upon receipt by the Escrow Agent
on or before the Release Date of a certificate signed by any officer of fonix
(an "Officer's Certificate") stating that with respect to the indemnification
obligations of the shareholders of AcuVoice set forth in Section 8.2, Damages
exist and specifying in reasonable detail the individual items of such Damages
included in the amount so stated, the date each such item was paid, or
properly accrued or arose, and the nature of the misrepresentation, breach of
warranty or claim to which such item is related, the Escrow Agent shall,
subject to the provisions of this Section 8, deliver to fonix out of the
Escrow Fund, as promptly as practicable, fonix Common Stock or other assets
held in the Escrow Fund having a value equal to such Damages. For the purpose
of compensating fonix for its Damages pursuant to this Agreement, fonix Common
Stock in the Escrow Fund shall be valued at the average closing "bid" price of
a share of fonix Common Stock for the ten (10) trading days immediately
preceding the Release Date, as reported on the Nasdaq SmallCap Market (the
"Indemnification Price"). In determining the amount of any Damage
attributable to a breach, any materiality standard contained in a
representation, warranty or covenant of fonix shall be disregarded.
8.5 Objections to Claims. At the time of delivery of any
Officer's Certificate to the Escrow Agent, a duplicate copy of such Officer's
Certificate shall be delivered to the Shareholders' Agent (defined in Section
8.7 below) and for a period of thirty (30) days after such delivery, the
Escrow Agent shall make no delivery of fonix Common Stock or other property
pursuant to Section 8.4 hereof unless the Escrow Agent shall have received
written authorization from the Shareholders' Agent to make such delivery.
After the expiration of such thirty (30) day period, the Escrow Agent shall
make delivery of fonix Common Stock or other property in the Escrow Fund in
accordance with Section 8.4 hereof, provided that no such payment or delivery
may be made if the Shareholders' Agent shall object in a written statement to
the claim made in the Officer's Certificate, and such statement shall have
been delivered to the Escrow Agent and to fonix prior to the expiration of
such thirty (30) day period.
8.6 Resolution of Conflicts and Arbitration.
(a) In case the Shareholders' Agent shall so object in
writing to any claim or claims by fonix made in any Officer's Certificate,
fonix shall have thirty (30) days to respond in a written statement to the
objection of the Shareholders' Agent. If after such thirty (30) day period
there remains a dispute as to any claims, the Shareholders' Agent and fonix
shall attempt in good faith for thirty (30) days to agree upon the rights of
the respective parties with respect to each of such claims. If the
Shareholders' Agent and fonix should so agree, a memorandum setting forth such
agreement shall be prepared and signed by both parties and shall be furnished
to the Escrow Agent. The Escrow Agent shall be entitled to rely on any such
memorandum and shall distribute the fonix Common Stock or other property from
the Escrow Fund in accordance with the terms thereof.
(b) If no such agreement can be reached after good faith
negotiation, either fonix or the Shareholders' Agent may, by written notice to
the other, demand arbitration of the matter unless the amount of the damage or
loss is at issue in pending litigation with a third party, in which event
arbitration shall not be commenced until such amount is ascertained or both
parties agree to arbitration; and in either such event the matter shall be
settled by arbitration conducted by one arbitrator. fonix and the
Shareholders' Agent shall agree on the arbitrator, provided that if fonix and
the Shareholders' Agent cannot agree on such arbitrator, either fonix or
Shareholders' Agent can request that the American Arbitration Association
select the arbitrator. The arbitrator shall set a limited time period and
establish procedures designed to reduce the cost and time for discovery while
allowing the parties an opportunity, adequate in the sole judgment of the
arbitrators, to discover relevant information from the opposing parties about
the subject matter of the dispute. The arbitrator shall rule upon motions to
compel or limit discovery and shall have the authority to impose sanctions,
including attorneys' fees and costs, to the same extent as a court of
competent law or equity, should the arbitrator determine that discovery was
sought without substantial justification or that discovery was refused or
objected to without substantial justification. The decision of the arbitrator
shall be written, shall be in accordance with applicable law and with this
Agreement, and shall be supported by written findings of fact and conclusion
of law which shall set forth the basis for the decision of the arbitrator.
The decision of the arbitrator as to the validity and amount of any claim in
such Officer's Certificate shall be binding and conclusive upon the parties to
this Agreement, and notwithstanding anything in Section 8.5 hereof, the Escrow
Agent shall be entitled to act in accordance with such decision and make or
withhold payments out of the Escrow Fund in accordance therewith.
(c) Judgment upon any award rendered by the arbitrator may
be entered in any court having jurisdiction. Any such arbitration shall be
held in Salt Lake County, Utah under the commercial rules then in effect of
the American Arbitration Association. For purposes of this Section 8.6(c), in
any arbitration hereunder in which any claim or the amount thereof stated in
the Officer's Certificate is at issue, fonix shall be deemed to be the
Non-Prevailing Party unless the arbitrators award fonix more than one-half
(1/2) of the amount in dispute, plus any amounts not in dispute; otherwise,
the AcuVoice shareholders for whom the Escrow Shares, Additional Escrow Shares
(if any) and the Escrow Cash have been deposited in the Escrow Fund shall be
deemed to be the Non-Prevailing Party. The Non-Prevailing Party to an
arbitration shall pay its own expenses, the fees of the arbitrator, the
administrative fee of the American Arbitration Association, and the expenses,
including attorneys' fees and costs, reasonably incurred by the other party to
the arbitration.
8.7 Shareholders' Agent.
(a) E. David Barton shall be constituted and appointed as
agent ("Shareholders' Agent") for and on behalf of the AcuVoice shareholders
to give and receive notices and communications, to authorize delivery to fonix
of the fonix Common Stock or other property from the Escrow Fund in
satisfaction of claims by fonix, to object to such deliveries, to agree to,
negotiate, enter into settlements and compromises of, and demand arbitration
and comply with orders of courts and awards of arbitrators with respect to
such claims, and to take all actions necessary or appropriate in the judgment
of the Shareholders' Agent for the accomplishment of the foregoing. Such
agency may be changed by the holders of a majority in interest of the Escrow
Fund from time to time upon not less than 10 days' prior written notice to
fonix. No bond shall be required of the Shareholders' Agent, and the
Shareholders' Agent shall receive no compensation for his services. Notices
or communications to or from the Shareholders' Agent shall constitute notice
to or from each of the AcuVoice shareholders.
(b) The Shareholders' Agent shall not be liable for any act
done or omitted hereunder as Shareholder' Agent while acting in good faith and
in the exercise of reasonable judgment and any act done or omitted pursuant to
the advice of counsel shall be conclusive evidence of such good faith. The
AcuVoice shareholders shall severally indemnify the Shareholders' Agent and
hold him harmless against any loss, liability or expense incurred without
gross negligence or bad faith on the part of the Shareholders' Agent and
arising out of or in connection with the acceptance or administration of his
duties hereunder.
(c) The Shareholders' Agent shall have reasonable access to
information about AcuVoice and the reasonable assistance of AcuVoice's
officers and employees for purposes of performing his duties and exercising
his rights hereunder, provided that the Shareholders' Agent shall treat
confidentially and not disclose any nonpublic information from or about
AcuVoice to anyone (except on a need to know basis to individuals who agree to
treat such information confidentially).
(d) fonix acknowledges that E. David Barton may have a
conflict of interest with respect to his duties as Shareholders' Agent, and in
such regard E. David Barton has informed fonix that he will act in the best
interests of AcuVoice shareholders.
8.8 Actions of the Shareholders' Agent. A decision, act,
consent or instruction of the Shareholders' Agent shall constitute a decision
of all AcuVoice shareholders for whom shares of fonix Common Stock otherwise
issuable to them are deposited in the Escrow Fund and shall be final, binding
and conclusive upon each such AcuVoice shareholder, and the Escrow Agent and
fonix may rely upon any decision, act, consent or instruction of the
Shareholders' Agent as being the decision, act, consent or instruction of each
and every such AcuVoice shareholder. The Escrow Agent and fonix are hereby
relieved from any liability to any person for any acts done by them in
accordance with such decision, act, consent or instruction of the
Shareholders' Agent.
8.9 Third-Party Claims. In the event fonix becomes aware of a
third-party claim which fonix believes may result in a demand against the
Escrow Fund, fonix shall notify the Shareholders' Agent of such claim, and the
Shareholders' Agent and the AcuVoice shareholders for whom shares of fonix
Common Stock otherwise issuable to them are deposited in the Escrow Fund shall
be entitled, at their expense, to participate in any defense of such claim.
fonix shall have the right in its sole discretion to settle any such claim.
In the event that the Shareholders' Agent has consented to any such
settlement, the Shareholders' Agent shall have no power or authority to object
under Section 8.5 or any other provision of this Section 8 to the amount of
any claim by fonix against the Escrow Fund for indemnity with respect to such
settlement.
9. General Provisions.
9.1 Notices. All notices and other communications hereunder
shall be in writing and shall be deemed duly delivered if delivered personally
(upon receipt), or three (3) business days after being mailed by registered or
certified mail, postage prepaid (return receipt requested), or one (1)
business day after it is sent by reputable nationwide overnight courier
service, or upon transmission, if sent via facsimile (with confirmation of
receipt) to the parties at the following address (or at such other address for
a party as shall be specified by like notice):
(a) if to fonix or Merger Sub, to:
fonix corporation
60 East South Temple
1225 Eagle Gate Tower
Salt Lake City, Utah 84111
Attention: Thomas A. Murdock
Fax: (801) 328-8778
Tel: (801) 328-0161
with a copy to:
Jeffrey M. Jones, Esq.
Durham, Evans, Jones & Pinegar
50 South Main Street, Suite 850
Salt Lake City, Utah 84144
Fax: (801) 538-2425
Tel: (801) 538-2424
(b) if to AcuVoice, to:
AcuVoice, Inc.
84 West Santa Clara Street
Suite 720
San Jose, CA 95113
Attn: David Barton
Fax: (408) 289-1201
Tel: (408) 289-1661
with a copy to:
Wilson Sonsini Goodrich & Rosati, P.C.
650 Page Mill Road
Palo Alto, CA 94304-1050
Attn: Aaron Alter, Esq.
Fax: (650) 493-6811
Tel: (650) 493-9300
(c) if to the Shareholders' Agent, to:
David Barton
84 West Santa Clara Street, Suite 720
San Jose, CA 95113
Fax: (408) 289-1201
Tel: (408) 289-1661
with a copy to:
Wilson Sonsini Goodrich & Rosati, P.C.
650 Page Mill Road
Palo Alto, CA 94304-1050
Attn: Aaron Alter, Esq.
Fax: (650) 493-6811
Tel: (650) 493-9300
9.2 Definitions. In this Agreement any reference to any event,
change, condition or effect being "material" with respect to any entity or
group of entities means any material event, change, condition or effect
related to the financial condition, properties, assets (including intangible
assets), liabilities, business, operations or results of operations of such
entity or group of entities. In this Agreement any reference to a "Material
Adverse Effect" with respect to any entity or group of entities means any
event, change or effect that is materially adverse tojthe financial condition,
properties; assets, liabilities, business, operations or results of operations
of such entity and its subsidiaries, taken as a whole. In this Agreement any
reference to a party's "knowledge" means such party's actual knowledge after
reasonable inquiry of officers, directors and other employees of such party
reasonably believed to have knowledge of such matters.
9.3 Counterparts. This Agreement may be executed in one or more
counterparts, all of which shall be considered one and the same agreement and
shall become effective when one or more counterparts have been signed by each
of the parties and delivered to the other parties, it being understood that
all parties need not sign the same counterpart.
9.4 Entire Agreement; Nonassignability; Parties in Interest.
This Agreement and the documents and instruments and other agreements
specifically referred to herein or delivered pursuant hereto, including the
Exhibits, the Schedules, including the AcuVoice Disclosure Schedule and the
fonix Disclosure Schedule (a) constitute the entire agreement among the
parties with respect to the subject matter hereof and supersede all prior
agreements and understandings, both written and oral, among the parties with
respect to the subject matter hereof except for the Confidentiality Agreement,
which shall continue in full force and effect, and shall survive any
termination of this Agreement, in accordance with its terms; (b) are not
intended to confer upon any other person any rights or remedies hereunder, and
shall not be assigned by operation of law or otherwise without the written
consent of the other party.
9.5 Severability. In the event that any provision of this
Agreement, or the application thereof becomes or is declared by a court of
competent jurisdiction to be illegal, void or unenforceable, the remainder of
this Agreement will continue in full force and effect and the application of
such provision to other persons or circumstances will be interpreted so as
reasonably to effect the intent of the parties hereto. The parties further
agree to replace such void or unenforceable provision of this Agreement with a
valid and enforceable provision that will achieve, to the extent possible, the
economic, business and other purposes of such void or unenforceable provision.
9.6 Remedies Cumulative. Except as otherwise provided herein,
any and all remedies herein expressly conferred upon a party will be deemed
cumulative with and not exclusive of any other remedy conferred hereby, or by
law or equity upon such party, and the exercise by a party of any one remedy
will not preclude the exercise of any other remedy.
9.7 Governing Law. This Agreement shall be governed by and
construed in accordance with the laws of Utah that might otherwise govern
under applicable principles of conflicts of law. Each of the parties hereto
irrevocably consents to the exclusive jurisdiction of any court located within
Salt Lake County, State of Utah, in connection with any matter based upon or
arising out of this Agreement or the matters contemplated hereby and it agrees
that process may be served upon it in any manner authorized by the laws of the
State of Utah for such persons and waives and covenants not to assert or plead
any objection which it might otherwise have to such jurisdiction and such
process.
9.8 Rules of Construction. The parties hereto agree that they
have been represented by counsel during the negotiation, preparation and
execution of this Agreement and, therefore, waive the application of any law,
regulation, holding or rule of construction providing that ambiguities in an
agreement or other document will be construed against the party drafting such
agreement or document.
9.9 Amendment. The Agreement may be amended by the parties
hereto, by action taken by their respective Board of Directors, at any time
before or after approval of the Merger by the shareholders of AcuVoice;
provided that following approval of the Merger by the shareholders of
AcuVoice, no amendment shall be made which by law requires the further
approval of such shareholders without obtaining such further approval. This
Agreement may not be amended except by an instrument in writing signed on
behalf of each of the parties hereto.
9.10 Expenses. Except with respect to the disbursement of
$400,000 of the Earnest Money by AcuVoice to fonix as set forth in Section 7.2
hereof, whether or not the Merger is consummated, all costs and expenses
incurred in connection with this Agreement, the Articles of Merger and the
transactions contemplated hereby and thereby shall be paid by the party
incurring such expense.
9.11 Extension; Waiver. At any time prior to the Effective
Time, each of AcuVoice and fonix, by action taken by its Board of Directors,
may, to the extent legally allowed, (i) extend the time for the performance of
any of the obligations or other acts of the other, (ii) waive any inaccuracies
in the representations and warranties made to it contained herein or in any
document delivered pursuant hereto and (iii) waive compliance with any of the
agreements or conditions for the benefit of it contained herein. Any
agreement on the part of a party hereto to any such extension or waiver shall
be valid only if set forth in an instrument in writing signed on behalf of
such party.
9.12 No Transfer. This Agreement and the rights and obligations
set forth herein may not be transferred or assigned by operation of law or
otherwise without the consent of each party hereto. This Agreement is binding
upon and will inure to the benefit of the parties hereto and their respective
successors and permitted assigns.
9.13 Further Assurances. Each party agrees to cooperate fully
with the other parties and to execute such further instruments, documents and
agreements and to give such further written assurances as may be reasonably
requested by any other party to evidence and reflect the transactions
described herein and contemplated hereby and to carry into effect the intents
and purposes of this Agreement.
9.14 Absence of Third Party Beneficiary Rights. No provision of
this Agreement is intended, nor will be interpreted, to provide to create any
third party beneficiary rights or any other rights of any kind in any client,
customer, affiliate, stockholder, employee, partner or any party hereto or any
other person or entity unless specifically provided otherwise herein, and,
except as so provided, all provisions will be personal solely between the
parties to this Agreement.
[REMAINDER OF PAGE LEFT INTENTIONALLY BLANK.
SIGNATURE PAGE FOLLOWS.]
<PAGE>
IN WITNESS WHEREOF, AcuVoice, fonix and Merger Sub have caused this
Agreement to be executed and delivered by each of them or their respective
officers "hereunto duly authorized, all as of the date first written above.
ACUVOICE, INC.
By: /s/ E. David Barton
------------------------------------
E. David Barton
President and Chief Executive Officer
fonix corporation
By: /s/ Thomas A. Murdock
--------------------------------------
Thomas A. Murdock
President and Chief Operating Officer
fonix ACQUISITION CORPORATION
By: /s/ Thomas A. Murdock
-------------------------------------
Thomas A. Murdock
President
